



# **PRECISION MEDICINE IMPROVING HEALTHCARE WITH DATA SCIENCE AND MACHINE LEARNING**

Editors:

**Prasad Lokulwar**

**Basant Kumar Verma**

**Mitu Sehgal**

**Kailash Kumar**

**Mohan Kolhe**

**Bentham Books**

# **Precision Medicine: Improving Healthcare with Data Science and Machine Learning**

Edited by

**Prasad Lokulwar**

*Department of Computer Science and Engineering  
GH Rasoni College of Engineering  
Nagpur, Maharashtra, India*

**Basant Kumar Verma**

*Department of Computer Science and Engineering  
Panipat Institute of Engineering and Technology  
Samalkha, Haryana, India*

**Mitu Sehgal**

*Department of CSE-AI and Data Science  
Panipat Institute of Engineering and Technology  
Samalkha, Haryana, India*

**Kailash Kumar**

*College of Computing and Informatics  
Saudi Electronic University  
Riyadh, Saudi Arabia*

&

**Mohan Kolhe**

*Hydrogen Energy & Sustainable Electrical Energy System  
at University of Agder, Norway*

## **Precision Medicine: Improving Healthcare with Data Science and Machine Learning**

Editors: Prasad Lokulwar, Basant Kumar Verma, Mitu Sehgal, Kailash Kumar & Mohan Kolhe

ISBN (Online): 979-8-89881-477-9

ISBN (Print): 979-8-89881-478-6

ISBN (Paperback): 979-8-89881-479-3

© 2026, Bentham Books imprint.

Published by Bentham Science Publishers Pte. Ltd. Singapore, in collaboration with Eureka Conferences, USA. All Rights Reserved.

First published in 2026.

## **BENTHAM SCIENCE PUBLISHERS LTD.**

### **End User License Agreement (for non-institutional, personal use)**

This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the ebook/echapter/ejournal (“**Work**”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.

Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: [permission@benthamscience.org](mailto:permission@benthamscience.org).

### **Usage Rules:**

1. All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.
2. You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it.
3. The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.

### ***Disclaimer:***

Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in the Work.

### ***Limitation of Liability:***

In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.

### **General:**

1. Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of Singapore. Each party agrees that the courts of the state of Singapore shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).
2. Your rights under this License Agreement will automatically terminate without notice and without the

need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.

3. You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.

**Bentham Science Publishers Pte. Ltd.**

No. 9 Raffles Place

Office No. 26-01

Singapore 048619

Singapore

Email: [subscriptions@benthamscience.net](mailto:subscriptions@benthamscience.net)



## CONTENTS

|  |    |
|--|----|
| FOREWORD .....   | i  |
| PREFACE .....  | ii |
| LIST OF CONTRIBUTORS .....   | iv |
| <b>CHAPTER 1 DEVELOPMENT AND PERFORMANCE ENHANCEMENT OF MACHINE LEARNING BASED APPROACHES FOR DETECTION OF SKIN DISEASES</b> ..... | 1  |
| <b>Krupali Dhawale and A. R. Patil Bhagat</b>  |    |
| <b>INTRODUCTION</b> .....  | 1  |
| <b>LITERATURE REVIEW</b> .....   | 3  |
| Identified Research Gap .....  | 8  |
| <i>Knowledge Gap</i> .....   | 8  |
| <i>Methodological Gap</i> .....  | 8  |
| <i>Population Gap</i> .....  | 9  |
| <b>TRADITIONAL DIAGNOSTIC APPROACHES</b> .....   | 9  |
| Medical Evaluation .....   | 9  |
| <i>Pathology through Histopathology</i> .....  | 9  |
| <i>Methods for Invasive Biopsies</i> .....   | 9  |
| <b>DEVELOPING MACHINE LEARNING APPLICATIONS IN DERMATOLOGY</b> .....   | 10 |
| Classifying Images and Identifying Patterns .....  | 10 |
| <i>Analysis of Dermoscopic Images</i> .....  | 10 |
| <i>Real-time Diagnosis</i> .....   | 11 |
| Early Detection and Evaluation of Severity .....   | 11 |
| <i>Automated Lesion Identification</i> .....   | 11 |
| <i>Severity Grading</i> .....  | 11 |
| Predictive Modelling for the Advancement of Disease .....  | 11 |
| <i>Forecasting Flare-ups</i> .....   | 11 |
| <i>Long-term Monitoring</i> .....  | 11 |
| <i>Merging Data to Provide a Complete Diagnosis</i> .....  | 11 |
| <i>Deep Learning-Based Methods</i> .....   | 12 |
| <i>Ensemble Methods</i> .....  | 12 |
| Convolutional Neural Networks (CNNs) .....   | 12 |
| Here is a list of CNNs .....   | 12 |
| <i>Pooling Layers</i> .....  | 12 |
| <i>Non-Linear Activation</i> .....   | 13 |
| <i>Fully Linked Layers</i> .....   | 13 |
| <i>Backpropagation and Training</i> .....  | 13 |
| Case Study: “Detection of Papulosquamous Skin Diseases” .....  | 13 |
| <i>Problem Statement:</i> .....  | 13 |
| <i>Objective</i> .....   | 13 |
| <i>Role of VGG16 in Papulosquamous Skin Diseases</i> .....   | 14 |
| <b>RESULT</b> .....  | 15 |
| <b>CONCLUSION</b> .....  | 17 |
| <b>REFERENCES</b> .....  | 18 |
| <b>CHAPTER 2 FOUNDATION OF DATA SCIENCE AND MACHINE LEARNING IN HEALTHCARE</b> .....   | 21 |
| <b>Jagvijay Singh, Anisha and Roshni Jha</b>   |    |
| <b>INTRODUCTION</b> .....  | 21 |
| Health Data Types .....  | 23 |

|  |    |
|--|----|
| <i>Clinical Trials</i> .....   | 23 |
| <i>Insurance Claims</i> .....  | 24 |
| <i>EHRs</i> .....  | 25 |
| <i>Integrating Complementary Evidence</i> .....                                  | 25 |
| Uses and Benefits of Data Models in Healthcare .....                             | 26 |
| <i>Improved Data Quality</i> .....   | 27 |
| <i>Greater Operational Efficiency</i> .....                                      | 27 |
| <i>Enhanced Predictive Analytics</i> .....                                       | 27 |
| <i>Transparent Audit Trails for Regulatory Compliance</i> .....                  | 28 |
| <i>Better Patient Engagement</i> .....   | 29 |
| Opportunity for Data Science and ML in Healthcare .....                          | 30 |
| Exploratory Data Analysis (EDA) Techniques for Medical Datasets .....            | 30 |
| <i>Data Cleaning</i> .....   | 31 |
| <i>Descriptive Statistics</i> .....  | 32 |
| <i>Visualization Techniques</i> .....  | 32 |
| <i>Dimensionality Reduction</i> .....  | 32 |
| <i>Statistical Testing</i> .....   | 33 |
| <i>Feature Relationships</i> .....   | 33 |
| Machine Learning in Healthcare .....   | 34 |
| <i>Disease Diagnosis and Prediction</i> .....                                    | 34 |
| <i>Personalized Medicine and Treatment Plans</i> .....                           | 35 |
| <i>Drug Discovery and Development</i> .....                                      | 35 |
| <i>Predictive Analytics for Patient Outcomes</i> .....                           | 36 |
| <i>Improving Operational Efficiency</i> .....                                    | 36 |
| Challenges of Implementing Data Science and Machine Learning in Healthcare ..... | 37 |
| <i>Data Quality and Infrastructure</i> .....                                     | 37 |
| <i>Compliance and Governance</i> .....   | 38 |
| <i>Skills</i> .....  | 38 |
| Application of Data Science in Healthcare .....                                  | 38 |
| <i>Predictive Analytics for Disease Prevention</i> .....                         | 39 |
| <i>Personalized Treatment Plans with Machine Learning</i> .....                  | 39 |
| <i>Improving Healthcare Operations with Big Data Analytics</i> .....             | 40 |
| <i>Enhancing Patient Engagement and Experience</i> .....                         | 40 |
| <i>Data Security and Privacy in Healthcare</i> .....                             | 41 |
| <i>Predictive Analytics</i> .....  | 41 |
| <i>Personalization of Treatment</i> .....  | 42 |
| <i>Analyzing the Error in Predictions</i> .....                                  | 42 |
| <i>Disease Outbreak Prediction</i> .....   | 42 |
| <i>Operational Efficiency</i> .....  | 43 |
| Deep Learning Applications in Medical Imaging .....                              | 43 |
| <i>Tumor Detection</i> .....   | 43 |
| <i>Tracking Tumor Development</i> .....  | 43 |
| <i>Blood Flow Quantification and Visualization</i> .....                         | 44 |
| <i>Medical Interpretation</i> .....  | 44 |
| <i>Diabetic Retinopathy</i> .....  | 44 |
| Case Studies of AI in Detecting Diseases .....                                   | 45 |
| <i>Cancer Detection</i> .....  | 45 |
| <i>Diabetes Management</i> .....   | 45 |
| <i>Heart Disease Prediction</i> .....  | 46 |
| <i>AI in Neurological Disorders</i> .....  | 47 |
| Future Directions in Healthcare Data Science .....                               | 47 |

|  |           |
|--|-----------|
| CONCLUSION .....   | 48        |
| REFERENCES .....   | 48        |
| <b>CHAPTER 3 GENOMICS DATA ANALYTICS: AN INNOVATIVE APPROACH TO<br/>PRECISION MEDICINE .....</b> | <b>51</b> |
| <b>Sorabh Gupta, Rashmi Makkar and Neha Bhatia</b>   |           |
| <b>INTRODUCTION .....</b>  | <b>51</b> |
| <b>BACKGROUND .....</b>  | <b>53</b> |
| Historical Development of Precision Medicine .....   | 53        |
| Key Concepts in Genomics .....   | 53        |
| <b>PERSONALIZED MEDICINE TRANSFORMS HEALTHCARE .....</b>   | <b>54</b> |
| <b>THE ROLE OF GENOMICS IN PERSONALIZED MEDICINE .....</b>                                       | <b>55</b> |
| <b>FOCAL CHALLENGES OF PERSONALIZED MEDICINE .....</b>   | <b>56</b> |
| Data Privacy and Security .....  | 57        |
| Social and Ethical Issues .....  | 57        |
| Regulatory Matters .....   | 58        |
| Economic Barriers .....  | 58        |
| Amalgamation into Medical Practice .....   | 59        |
| Collaboration Across Fields .....  | 59        |
| Challenges in Science .....  | 60        |
| <b>DATA ANALYTICS IN GENOMIC STUDIES .....</b>   | <b>60</b> |
| NGS Read Placement .....   | 60        |
| Variants .....   | 61        |
| Non-Variant NGS Data .....   | 61        |
| Genomics Statistics .....  | 62        |
| Genomics Data Security .....   | 62        |
| <b>MACHINE LEARNING PERSPECTIVES ON PERSONALIZED MEDICINE .....</b>                              | <b>63</b> |
| <b>PERSONALIZED MEDICINE APPLICATIONS .....</b>  | <b>63</b> |
| Oncology .....   | 63        |
| Intervention and Diagnosis .....   | 64        |
| Pharmacogenomics .....   | 64        |
| Cardiovascular Diseases .....  | 65        |
| Rare Genetic Disorders .....   | 65        |
| Neurological Issues .....  | 65        |
| Infectious Diseases .....  | 66        |
| Managing Diabetes .....  | 66        |
| Developing Drugs .....   | 67        |
| <b>PRECISION MEDICINE CASE STUDIES .....</b>   | <b>67</b> |
| Oncology .....   | 67        |
| Cardiovascular Disease .....   | 68        |
| Neurological Issues .....  | 68        |
| <b>IT-ENABLED PRECISION MEDICINE AND GENOMICS .....</b>  | <b>68</b> |
| Genomic Analysis and Bioinformatics .....  | 68        |
| Data Mining/ML Applications .....  | 68        |
| Data Analysis and Genetic Sequencing Technology .....  | 69        |
| Computerized Decision-Support Systems (CDSS) .....   | 69        |
| EHR Integration .....  | 69        |
| Risk Evaluations and Predictive Models .....   | 69        |
| Telemedicine and Remote Monitoring .....   | 69        |
| <b>THE FUTURE OF PERSONALIZED MEDICINE .....</b>   | <b>69</b> |
| Genomic Medicine Advances .....  | 70        |

|  |    |
|--|----|
| AI and ML .....  | 70 |
| Discovery of Biomarkers .....                                      | 70 |
| Research Cooperation and Data Exchange .....                       | 71 |
| Custom Drugs .....   | 71 |
| <b>CONCLUSION AND SUGGESTIONS</b> .....                            | 72 |
| Suggestions: .....   | 72 |
| <b>REFERENCES</b> .....  | 72 |
| <b>CHAPTER 4 IMAGING DATA ANALYSIS IN PRECISION MEDICINE</b> ..... | 81 |
| <b>Sayali R. Tajane and Shivraj Guduri</b>                         |    |
| <b>INTRODUCTION</b> .....  | 81 |
| <b>MACHINE LEARNING IN IMAGING DATA ANALYSIS</b> .....             | 83 |
| Image Segmentation .....   | 83 |
| Classification and Feature .....                                   | 84 |
| <i>Case Study</i> .....  | 84 |
| Imaging in Multiple Modes .....                                    | 85 |
| <i>Benefits</i> .....  | 85 |
| New Advancements and Challenges .....                              | 85 |
| <i>Patterns</i> .....  | 85 |
| <i>Challenges</i> .....  | 86 |
| <b>DATA PREPROCESSING AND AUGMENTATION</b> .....                   | 86 |
| Preprocessing of Data .....  | 86 |
| <i>Reducing Noise</i> .....  | 86 |
| <i>There are Different Types of Registration</i> .....             | 87 |
| Supplementing Data .....   | 87 |
| Rotation and Scaling .....   | 87 |
| Flipping .....   | 87 |
| Adding Noise .....   | 87 |
| Cropping and Padding .....   | 88 |
| Variations in Intensity .....                                      | 88 |
| <b>ADDITIONAL CONSIDERATIONS</b> .....                             | 88 |
| Synthetic Data Generation .....                                    | 88 |
| Pipelines .....  | 88 |
| <b>IMAGING PRECISION WORKFLOW</b> .....                            | 89 |
| Data Acquisition .....   | 89 |
| Data Preprocessing .....   | 89 |
| Feature Extraction and Classification .....                        | 89 |
| Multi-Modal Integration .....                                      | 90 |
| Insights and Applications .....                                    | 90 |
| <b>APPLICATIONS OF IMAGING DATA IN PRECISION MEDICINE</b> .....    | 90 |
| Oncology .....   | 90 |
| Cardiovascular Disease Analysis .....                              | 91 |
| Neurological Disorders .....                                       | 91 |
| Genetic Disorders and Rare Diseases .....                          | 91 |
| Future Directions .....  | 91 |
| <b>PERSONALIZED MEDICINE: REVOLUTIONIZING HEALTHCARE</b> .....     | 92 |
| Genetics and Medicine .....  | 92 |
| Tailored Treatments .....  | 92 |
| AI in Healthcare .....   | 94 |
| Targeted Therapies .....   | 94 |
| Enhanced Patient Care .....  | 95 |

|  |     |
|--|-----|
| Future of Medicine .....   | 95  |
| <b>REVOLUTIONIZING HEALTHCARE WITH IMAGING DATA</b> .....              | 96  |
| Imaging Modalities .....   | 96  |
| Data Standardization .....   | 97  |
| Feature Analysis .....   | 97  |
| Clinical Integration .....   | 97  |
| Decision Support .....   | 98  |
| <b>FUTURE SCOPE</b> .....  | 98  |
| Integration of AI and Imaging .....                                    | 98  |
| <i>Utilizing Edge Computing for Real-Time Image Analysis</i> .....     | 98  |
| <i>Creating Clinically Useful Explainable AI Models</i> .....          | 98  |
| Emerging Technologies .....  | 99  |
| <i>Using Quantum Computing to Speed Up Image Analysis</i> .....        | 99  |
| <i>Generative Models for Simulating Imaging Data</i> .....             | 99  |
| Federated Learning in Medical Imaging .....                            | 99  |
| <i>Keeping Data Private While Collaborating</i> .....                  | 99  |
| <i>Better Model Performance Through Collaboration</i> .....            | 100 |
| Ethical AI in Medical Imaging .....                                    | 100 |
| <i>Reducing Bias in AI Algorithms</i> .....                            | 100 |
| <i>Accountability and Transparency</i> .....                           | 100 |
| <b>CONCLUSION</b> .....  | 100 |
| <b>REFERENCES</b> .....  | 101 |
| <b>CHAPTER 5 ELECTRONIC HEALTH RECORDS (EHR) AND CLINICAL DECISION</b> |     |
| <b>SUPPORT SYSTEM</b> .....  | 103 |
| <b>Shankar Gadve and Goldi Soni</b>                                    |     |
| <b>INTRODUCTION</b> .....  | 103 |
| <b>BACKGROUND</b> .....  | 105 |
| Problem Identified .....   | 108 |
| Challenges .....   | 109 |
| <b>METHODOLOGY</b> .....   | 109 |
| Systematic Framework .....   | 111 |
| Proposed Participants, Assets, and Transactions .....                  | 112 |
| <b>CONSENT MANAGER AND SECURITY LAYER</b> .....                        | 115 |
| <b>GENERAL PURPOSE TREE</b> .....                                      | 116 |
| <b>CONSENT MODEL AND CONSENT LIST</b> .....                            | 117 |
| <b>CONCLUSION</b> .....  | 118 |
| <b>REFERENCES</b> .....  | 118 |
| <b>CHAPTER 6 PHARMACOGENOMICS AND DRUG DEVELOPMENT</b> .....           | 121 |
| <b>Ragini Vishwakarma and Smriti Mall</b>                              |     |
| <b>INTRODUCTION</b> .....  | 121 |
| <b>PRESENT SCENARIO IN DRUG DISCOVERY AND DEVELOPMENT</b> .....        | 122 |
| <b>PHARMACOGENETICS</b> .....  | 127 |
| Drug Response .....  | 128 |
| <i>Impact of Genetic Variability on Drug Response</i> .....            | 129 |
| <i>Pharmacogenomic Biomarkers</i> .....                                | 131 |
| <b>CONCLUSION</b> .....  | 137 |
| <b>ACKNOWLEDGEMENTS</b> .....  | 137 |
| <b>REFERENCES</b> .....  | 138 |
| <b>CHAPTER 7 PREDICTIVE MODELING AND PATIENT STRATIFICATION</b> .....  | 143 |

**Krupali Dhawale, Dhananjay Bhagat and Parul Dubey**

|  |     |
|--|-----|
| <b>INTRODUCTION: PRECISION MEDICINE (TRANSFORMING HEALTHCARE)</b> .....  | 143 |
| Patient Stratification Overview .....  | 144 |
| Related Work .....   | 145 |
| An Outline of the Transition from Traditional to Patient-centered Medicine via Predictive Modeling in Healthcare ..... | 146 |
| Predictive Modeling and Patient Stratification Using Technology .....  | 147 |
| Predictive Analytics Applications in Healthcare Organizations in the Real World .....                                  | 150 |
| <i>Models of Chronic Disease Risk Prediction</i> .....   | 151 |
| <i>AI-Assisted Rare Disease Diagnosis</i> .....  | 151 |
| <i>Personalized Treatments for Cancer Using Genetic Markers</i> .....  | 151 |
| <i>Artificial Intelligence (AI) Chatbots for E-commerce</i> .....  | 152 |
| <i>Future Directions and Challenges</i> .....  | 152 |
| <b>CONCLUSION</b> .....  | 152 |
| <b>REFERENCES</b> .....  | 153 |

**CHAPTER 8 ETHICAL AND REGULATORY CONSIDERATIONS FOR PRECISION**

|  |     |
|--|-----|
| <b>MEDICINE</b> .....  | 155 |
| <b>Pranali Dhawas, Mangala Madankar, Vaishali Shende and Shruti Thakur</b>                       |     |
| <b>INTRODUCTION TO PRECISION MEDICINE</b> .....  | 155 |
| Historical Evolution and Key Advancements .....  | 157 |
| Key milestones in its evolution include: .....   | 157 |
| <b>PRECISION MEDICINE AND PERSONALIZED MEDICINE</b> .....  | 158 |
| Personalized Medicine .....  | 158 |
| Precision Medicine .....   | 158 |
| Complementarity between the Two Concepts .....   | 159 |
| <b>SCOPE AND OBJECTIVE OF PRECISION MEDICINE</b> .....   | 159 |
| Enhanced Diagnostic Accuracy .....   | 159 |
| Personalized Treatments .....  | 159 |
| Preventive Strategies .....  | 160 |
| <b>TRANSFORMATIVE IMPACT OF PRECISION MEDICINE ON HEALTHCARE</b> .....                           | 160 |
| These Methods Improve Both Medical Diagnosis and Personalized Treatments .....                   | 160 |
| Personalized Treatment Methods Enhance Treatment Effectiveness and Lower Side Effect Risks ..... | 160 |
| The New Ways to Treat Difficult Health Conditions .....  | 160 |
| <b>NEED FOR ADDRESSING ETHICAL CHALLENGES AND REGULATORY FRAMEWORKS</b> .....                    | 161 |
| Healthcare Disparities .....   | 161 |
| Data Representation .....  | 161 |
| Global Accessibility .....   | 161 |
| Informed Consent and Patient Autonomy .....  | 162 |
| Data Privacy and Security .....  | 162 |
| Minimizing Potential Harms .....   | 162 |
| Adapting Regulations to Innovation .....   | 162 |
| <b>ETHICAL ISSUES IN PRECISION MEDICINE</b> .....  | 162 |
| Physician and Patient Education .....  | 163 |
| Data Privacy and Security .....  | 163 |
| Patients' Interests .....  | 163 |
| Justice .....  | 163 |
| Stigmatization .....   | 164 |
| Accessibility .....  | 164 |

|   |            |
|---|------------|
| Economic Challenges .....   | 164        |
| <b>REGULARIZATION OF CHALLENGES IN PRECISION MEDICINE .....</b>                             | <b>164</b> |
| Ethical Governance .....  | 164        |
| Regulatory Frameworks .....   | 165        |
| Patients' Rights and Safety .....   | 165        |
| Other Emerging Challenges .....   | 165        |
| Collaboration and Stakeholder Engagement .....  | 166        |
| Promoting Accessibility and Equity .....  | 166        |
| <b>ALIGNING ETHICAL STANDARDS AND REGULATORY FRAMEWORKS .....</b>                           | <b>166</b> |
| Strategies for Harmonizing Global Ethical Standards .....                                   | 166        |
| Enhancing Patient Education and Genomic Literacy .....                                      | 167        |
| Strengthening Collaboration Between Clinicians, Researchers, and Policymakers .....         | 167        |
| <b>EVOLUTION OF PRECISION MEDICINE .....</b>  | <b>168</b> |
| Key Milestones in the Development of Precision Medicine .....                               | 168        |
| Future Trends and Possibilities .....   | 168        |
| Vision for a Globally Inclusive and Ethically Sound Healthcare Ecosystem .....              | 169        |
| <b>CONCLUSION .....</b>   | <b>169</b> |
| <b>REFERENCES: .....</b>  | <b>170</b> |
| <br>  |            |
| <b>CHAPTER 9 IMPLEMENTING CHALLENGES AND BEST PRACTICES IN PRECISION<br/>MEDICINE .....</b> | <b>172</b> |
| <b>Neha Bhatia, Suman Kumari and Sandeep Kumar</b>  |            |
| <b>INTRODUCTION .....</b>   | <b>172</b> |
| <b>CHALLENGES IN PRECISION MEDICINE .....</b>   | <b>173</b> |
| Data Management and Big Data Challenges .....   | 174        |
| <i>Volume and Complexity of Data .....</i>  | <i>174</i> |
| <i>Data Storage and Security .....</i>  | <i>174</i> |
| <i>Data Interpretation Challenges .....</i>   | <i>174</i> |
| <b>FINANCIAL AND ECONOMIC CHALLENGES .....</b>  | <b>175</b> |
| High Cost of Genetic Testing and Treatment .....  | 175        |
| Limited Insurance Coverage and Reimbursement Policies .....                                 | 175        |
| <i>Solutions .....</i>  | <i>175</i> |
| <b>WORKFORCE AND TRAINING LIMITATIONS .....</b>   | <b>176</b> |
| Shortage of Skilled Professionals .....   | 176        |
| Training Gaps in Genomics and Bioinformatics .....  | 176        |
| <i>Solutions .....</i>  | <i>176</i> |
| <b>REGULATORY AND ETHICAL CHALLENGES .....</b>  | <b>176</b> |
| Slow Regulatory Approval Processes .....  | 176        |
| Ethical Concerns in Genetic Data Usage .....  | 176        |
| <i>Solutions .....</i>  | <i>177</i> |
| <b>INFRASTRUCTURE AND IMPLEMENTATION BARRIERS .....</b>                                     | <b>177</b> |
| Integration with Existing Healthcare Systems .....  | 177        |
| Limited Access to Precision Medicine in Community Settings .....                            | 177        |
| <i>Solutions .....</i>  | <i>177</i> |
| <b>IDENTIFYING DISTINCT PATIENT GROUPINGS AND SUBGROUPS .....</b>                           | <b>177</b> |
| <b>INCLUDING SEVERAL MORBIDITIES .....</b>  | <b>178</b> |
| <b>OBTAINING REAL-TIME DATA .....</b>   | <b>180</b> |
| <b>BEST PRACTICES IN IMPLEMENTING PRECISION MEDICINE .....</b>                              | <b>181</b> |
| Future-ready Technology & Strategy .....  | 181        |
| Patient Engagement in Precision Medicine .....  | 181        |
| Personalized Communication .....  | 181        |

|   |     |
|---|-----|
| Empowerment Through Education .....                                     | 182 |
| Digital Engagement for Better Access .....                              | 182 |
| EHR Integration .....   | 182 |
| Support Systems Beyond Medical Treatment .....                          | 182 |
| <b>USE OF AI AND ML TECHNOLOGIES IN IMPLEMENTING PRECISION MEDICINE</b> | 183 |
| <b>CONCLUSION</b> .....   | 184 |
| <b>REFERENCES</b> .....   | 185 |

|   |     |
|---|-----|
| <b>CHAPTER 10 PRECISION MEDICINE: IMPROVING HEALTHCARE WITH DATA SCIENCE AND MACHINE LEARNING</b> .....                                 | 189 |
| <b>Prashant Khobragade, Ashwini Yerlekar, Abhijit Titarmare, Payal Ghutke, Neha Purohit, Anand Babu Kotta and Praveen Kumar Dhankar</b> |     |
| <b>INTRODUCTION</b> .....   | 190 |
| Scope of Precision Medicine .....   | 192 |
| Evolution of Traditional Healthcare to Personalized Medicine .....  | 192 |
| Data Science and Machine Learning in Precision Medicine .....   | 193 |
| <b>THE CHALLENGES IN TRADITIONAL HEALTHCARE APPROACHES</b> .....  | 193 |
| One-Size-Fits-All Treatment Limitations .....   | 193 |
| Variability in Patient Response to Treatments .....   | 194 |
| Data Fragmentation across Healthcare Systems .....  | 194 |
| <b>ROLE OF DATA SCIENCE IN PRECISION MEDICINE</b> .....   | 196 |
| Understanding Big Data in Healthcare .....  | 196 |
| Data Integration and Management Challenges .....  | 196 |
| <b>MACHINE LEARNING IN PRECISION MEDICINE</b> .....   | 197 |
| Supervised Learning Algorithms .....  | 197 |
| <i>Support Vector Machines</i> .....  | 197 |
| <i>Random Forests</i> .....   | 198 |
| Unsupervised Learning Techniques .....  | 198 |
| <i>K-Means Clustering</i> .....   | 198 |
| <i>PCA</i> .....  | 199 |
| Deep Learning and Neural Networks in Healthcare .....   | 199 |
| Predictive Analytics for Disease Diagnosis and Prognosis .....  | 200 |
| <b>KEY APPLICATIONS OF PRECISION MEDICINE USING MACHINE LEARNING</b> .....  | 200 |
| Disease Diagnosis and Early Detection .....   | 200 |
| Personalized Treatment Plans and Therapy Optimization .....   | 201 |
| Drug Discovery and Development .....  | 202 |
| Biomarker Identification for Disease Prediction .....   | 202 |
| Real-Time Monitoring and Adaptive Therapies .....   | 203 |
| <b>CASE STUDY: APPLICATION OF MACHINE LEARNING IN ONCOLOGY</b> .....  | 204 |
| Overview of Cancer as a Case Study for Precision Medicine .....   | 204 |
| Identifying Genetic Markers for Targeted Therapies .....  | 204 |
| Outcomes and Impact on Patient Care .....   | 205 |
| <b>RESULTS AND DISCUSSION</b> .....   | 205 |
| Predictive Accuracy of ML Models .....  | 205 |
| Reduction in Adverse Drug Reactions .....   | 207 |
| Identification of Novel Disease Subtypes .....  | 208 |
| Comparative Analysis of ML Algorithms Used .....  | 209 |
| Discussion on Clinical Impact of Findings .....   | 211 |
| Implications for Future Healthcare Practices .....  | 212 |
| <b>CHALLENGES AND BARRIERS TO IMPLEMENTATION</b> .....  | 214 |
| Integration of Heterogeneous Data Sources .....   | 214 |

|   |            |
|---|------------|
| Collaboration between Data Scientists and Clinicians .....                            | 214        |
| Scalability and Infrastructure Constraints .....                                      | 215        |
| <b>FUTURE TRENDS IN PRECISION MEDICINE AND MACHINE LEARNING .....</b>                 | <b>215</b> |
| Emerging Technologies .....   | 215        |
| Digital Twins in Healthcare .....   | 215        |
| <b>CONCLUSION .....</b>   | <b>216</b> |
| <b>REFERENCES .....</b>   | <b>216</b> |
| <br>  |            |
| <b>CHAPTER 11 DEEP LEARNING MODELS FOR DR PREDICTION: A COMPARATIVE</b>               |            |
| <b>ANALYSIS OF CNN, RNN, AND ENSEMBLE METHODS .....</b>                               | <b>220</b> |
| <b>R. S. M. Lakshmi Patibandla, B. Tarakeswara Rao and Ramakrishna Murthy Malla</b>   |            |
| <b>INTRODUCTION .....</b>   | <b>220</b> |
| <b>DEEP LEARNING FOR DR PREDICTION .....</b>  | <b>222</b> |
| Convolutional Neural Networks (CNN) .....   | 222        |
| Recurrent Neural Networks (RNNs) .....  | 223        |
| Boosting Accuracy in DR Prediction .....  | 225        |
| Comparative Efficacy .....  | 227        |
| Limitations and Future Directions .....   | 228        |
| <b>CHALLENGES AND CONSIDERATIONS .....</b>  | <b>228</b> |
| Data Quality Impact .....   | 229        |
| Importance of Data Quantity .....   | 229        |
| Data Strategies for Improved DR Prediction .....                                      | 229        |
| Interpretability is Important for DR Diagnosis .....                                  | 230        |
| The Challenges of Interpretability .....  | 230        |
| Emerging Solutions and Future Directions .....  | 230        |
| Exploration of the Ethical Considerations Using Deep Learning for DR Prediction ..... | 231        |
| Data Privacy and Security .....   | 231        |
| Taking Care of Ethical Issues .....   | 232        |
| <b>FUTURE DIRECTIONS AND CONCLUSION .....</b>   | <b>232</b> |
| <b>REFERENCES .....</b>   | <b>233</b> |
| <br>  |            |
| <b>CHAPTER 12 GLOBAL PERSPECTIVE ON PRECISION MEDICINE AND FUTURE</b>                 |            |
| <b>TRENDS AND EMERGING TECHNOLOGIES .....</b>   | <b>236</b> |
| <b>Shally, Nisha Wadhawan and Ritika</b>  |            |
| <b>INTRODUCTION .....</b>   | <b>236</b> |
| History of Precision Medicine .....   | 238        |
| Role in Disease Prevention, Diagnosis, and Treatment .....                            | 239        |
| Potential of Precision Medicine .....   | 240        |
| Financing Precision Medicine for Cancer in Poorer Countries .....                     | 240        |
| <i>Stagnant Global Health Funding for Non-Communicable Diseases</i> .....             | 241        |
| <i>Innovative Financing Case Studies</i> .....  | 242        |
| Emerging Technologies in Precision Medicine .....                                     | 242        |
| <i>Genomics</i> .....   | 243        |
| <i>Genetics</i> .....   | 243        |
| <i>Genetic Sequencing</i> .....   | 243        |
| <i>Next-Generation Sequencing</i> .....   | 244        |
| <i>CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)</i> .....       | 244        |
| <i>Pharmacogenetics</i> .....   | 245        |
| <i>Biomarkers</i> .....   | 245        |
| <i>Biobanking</i> .....   | 246        |
| <i>Biomarker discovery</i> .....  | 247        |
| Personalized Care and Cancer Research via the Use of AI and ML .....                  | 247        |

|  |     |
|--|-----|
| <i>Increased Partnerships Between Pharmaceutical and Software Firms</i> .....        | 248 |
| <i>Growing Use of Biologics and Biocompatible Fabricated Bone Grafts</i> .....       | 248 |
| <i>High Cost Associated with Implementation and Integration</i> .....                | 249 |
| <i>Wearable Devices and Real-Time Health Monitoring</i> .....                        | 249 |
| Changes in Infrastructure and Policy in Personalised and Precision Medicine .....    | 249 |
| Precision Medicine Pipeline .....  | 251 |
| <i>Data Acquisition and Storage</i> .....  | 251 |
| <i>Information Access and Research</i> .....   | 251 |
| <i>Transforming Clinical Trials</i> .....  | 252 |
| <i>Societal Benefit</i> .....  | 252 |
| Technical Challenges and Ethical Considerations .....                                | 253 |
| <i>Implementing Biomarkers and Molecular Diagnostics in Precision Medicine</i> ..... | 254 |
| <b>CONCLUSION</b> .....  | 254 |
| <b>REFERENCES</b> .....  | 255 |
| <b>SUBJECT INDEX</b> .....   | 479 |

## FOREWORD

When I read the manuscript before writing this foreword, I saw a lot of interesting aspects that I wanted to share with you. The book is best characterized as brief but thorough. In just 12 chapters, there is more valuable material than in most books twice its size. For this reason, I am very happy to submit this foreword.

The integration of data science and machine learning into the realm of healthcare is reshaping the future of medicine, offering unprecedented opportunities to personalize treatment and improve patient outcomes. Precision medicine represents a significant paradigm shift, moving away from the traditional one-size-fits-all approach to more targeted, individualized care. This evolution is made possible by the confluence of vast datasets, advanced analytical tools, and collaborative interdisciplinary efforts.

The book *Precision Medicine: Improving Healthcare with Data Science and Machine Learning* delves into the transformative power of these technologies, highlighting their potential to revolutionize various aspects of healthcare, including disease diagnosis, prognosis, and treatment. The comprehensive coverage of methodologies, applications, and case studies presented in this volume provides valuable insights into the cutting-edge research driving precision medicine forward.

This timely volume addresses both the technical and ethical dimensions of precision medicine, offering a balanced perspective on the promises and challenges of data-driven healthcare. The collaborative contributions from experts across diverse fields underscore the importance of cross-disciplinary partnerships in realizing the full potential of precision medicine.

As healthcare systems worldwide strive to improve patient care and efficiency, the knowledge and innovations shared in this book will serve as an essential resource for researchers, clinicians, and data scientists. It is with great enthusiasm that I commend the authors and editors for their dedication to advancing this critical field, and I trust that this book will inspire further exploration and collaboration in the pursuit of precision medicine.

**Shruti A. Thakur**

Department of Computer Science and Engineering  
G H Rasoni College of Engineering  
Nagpur, Maharashtra, India

## PREFACE

The advent of precision medicine marks a transformative shift in healthcare, where treatments and interventions are tailored to the unique characteristics of individual patients. The main reason for this paradigm shift is the fast progress in data science and machine learning, which has allowed researchers and clinicians to use huge amounts of data to make more accurate diagnoses, better predictions about the future, and more personalized treatment plans. The convergence of these fields holds immense promise for improving patient outcomes, optimizing healthcare delivery, and advancing the understanding of complex diseases.

This book, *Precision Medicine: Improving Healthcare with Data Science and Machine Learning*, aims to provide a comprehensive overview of the pivotal role that data-driven technologies play in modern healthcare. It brings together cutting-edge research, methods, and applications that show how machine learning algorithms and big data analytics are changing different parts of precision medicine, such as clinical decision support systems, predictive modeling, and genomic analysis and biomarker discovery.

### Key Features

- Comprehensive exploration of the intersection between precision medicine, data science, and machine learning.
- Detailed case studies and real-world applications in genomic analysis, biomarker discovery, and personalized therapies.
- Insightful discussions on ethical considerations, data privacy, and regulatory challenges.
- Contributions from leading experts in the fields of healthcare informatics, computational biology, and clinical research.
- Practical guidance on implementing machine learning algorithms in clinical settings.
- Future perspectives on the evolving landscape of precision medicine and data-driven healthcare.

The chapters presented in this volume have been carefully curated to offer both foundational knowledge and advanced insights, making the book accessible to a wide audience, including researchers, healthcare professionals, data scientists, and students. The interdisciplinary nature of precision medicine requires a collaborative approach, and this book serves as a bridge between the domains of computational science, medicine, and healthcare informatics.

We extend our gratitude to the contributing authors, whose expertise and dedication have enriched this volume. Their work underscores the transformative potential of data science and machine learning in addressing the challenges of modern medicine. We also acknowledge Bentham Science for their support in bringing this project to fruition.

It is our hope that this book will serve as a valuable resource for those seeking to harness the power of data science and machine learning to drive innovation and improve patient care in the era of precision medicine.

**Prasad Lokulwar**

Department of Computer Science and Engineering  
GH Rasoni College of Engineering  
Nagpur, Maharashtra, India

**Basant Kumar Verma**

Department of Computer Science and Engineering  
Panipat Institute of Engineering and Technology  
Samalkha, Haryana, India

**Mitu Sehgal**

Department of CSE-AI and Data Science  
Panipat Institute of Engineering and Technology  
Samalkha, Haryana, India

**Kailash Kumar**

College of Computing and Informatics  
Saudi Electronic University  
Riyadh, Saudi Arabia

&

**Mohan Kolhe**

Hydrogen Energy & Sustainable Electrical Energy System  
at University of Agder, Norway

## List of Contributors

|                              |  |
|------------------------------|--|
| <b>A. R. Patil Bhagat</b>    | Department of Computer Technology, Yeshwantrao Chavan College of Engineering, Nagpur, India  |
| <b>Anisha</b>                | Department of CSE-AIDS, Panipat Institute of Engineering and Technology, Samalkha, India   |
| <b>Ashwini Yerlekar</b>      | Department of CSE (AI&ML), S. B. Jain Institute of Technology, Management and Research, Nagpur, India  |
| <b>Abhijit Titarmare</b>     | Department of Electronics and Telecommunication Engineering, G. H. Rasoni College of Engineering, Nagpur, India  |
| <b>Anand Babu Kotta</b>      | Department of Mechanical Engineering, G. H. Rasoni College of Engineering, Nagpur, India   |
| <b>B. Tarakeswara Rao</b>    | Department of CSE, KKR & KSR Institute of Technology and Sciences, Guntur, Andhra Pradesh, India   |
| <b>Dhananjay Bhagat</b>      | Department of Computer Engineering and Technology, School of Computer Science and Engineering, Dr. Vishwanath Karad, MIT World Peace University, Pune, India |
| <b>Goldi Soni</b>            | Amity School of Engineering & Technology, Amity University, Chhattisgarh, Raipur, India  |
| <b>Jagvijay Singh</b>        | Eduvate Consultancy Pvt. Ltd., Gr.Noida, U.P., India   |
| <b>Krupali Dhawale</b>       | Department of Computer Technology, Yeshwantrao Chavan College of Engineering, Nagpur, India  |
| <b>Mangala Madankar</b>      | Department of Computer Science & Engineering, G. H. Rasoni College of Engineering, Nagpur, India   |
| <b>Neha Bhatia</b>           | Department of Information Technology, Panipat Institute of Engineering & Technology, Panipat, Haryana, India   |
| <b>Neha Purohit</b>          | Department of Computer Science and Engineering, G. H. Rasoni College of Engineering, Nagpur, India   |
| <b>Nisha Wadhawan</b>        | School of Engineering & Technology, Apeejay Satya University, Gurugram, India  |
| <b>Parul Dubey</b>           | Symbiosis Institute of Technology, Nagpur Campus, Symbiosis International (Deemed University), Pune, India   |
| <b>Pranali Dhawas</b>        | Department of Artificial Intelligence, G. H. Rasoni College of Engineering, Nagpur, India  |
| <b>Prashant Khobragade</b>   | Department of Computer Science and Engineering, G. H. Rasoni College of Engineering, Nagpur, India   |
| <b>Payal Ghutke</b>          | Department of Electronics Engineering, G. H. Rasoni College of Engineering, Nagpur, India  |
| <b>Praveen Kumar Dhankar</b> | Symbiosis Institute of Technology, Nagpur Campus, Symbiosis International (Deemed University), Pune, India   |
| <b>Roshni Jha</b>            | Department of CSE-AIDS, Panipat Institute of Engineering and Technology, Samalkha, India   |

|                                    |   |
|------------------------------------|---|
| <b>Rashmi Makkar</b>               | Department of Information Technology, Panipat Institute of Engineering & Technology, Panipat, Haryana, India                      |
| <b>Ragini Vishwakarma</b>          | Molecular Plant Pathology Laboratory Department of Botany, Deen Dayal Upadhyaya Gorakhpur University, Gorakhpur, UP-273009, India |
| <b>R. S. M. Lakshmi Patibandla</b> | Department of CSE, Koneru Lakshmaiah Education Foundation, Guntur, Andhra Pradesh, India  |
| <b>Ramakrishna Murthy Malla</b>    | Department of CSE, Anil Neerukonda Institute of Technology and Sciences, Visakhapatnam, Andhra Pradesh, India                     |
| <b>Ritika</b>                      | School of Engineering & Technology, Apeejay Satya University, Gurugram, India   |
| <b>Sorabh Gupta</b>                | Department of Information Technology, Panipat Institute of Engineering & Technology, Panipat, Haryana, India                      |
| <b>Sayali R. Tajane</b>            | Department of Computer Science Engineering, G.H. Rasoni College of Engineering, Nagpur, India                                     |
| <b>Shivraj Guduri</b>              | Department of Artificial intelligence, G.H. Rasoni College of Engineering, Nagpur, India  |
| <b>Shankar Gadve</b>               | Amity School of Engineering & Technology, Amity University, Chhattisgarh, Raipur, India   |
| <b>Smriti Mall</b>                 | Molecular Plant Pathology Laboratory Department of Botany, Deen Dayal Upadhyaya Gorakhpur University, Gorakhpur, UP-273009, India |
| <b>Shruti Thakur</b>               | Department of Computer Science & Engineering, G. H. Rasoni College of Engineering, Nagpur, India                                  |
| <b>Suman Kumari</b>                | Department of Information Technology, Panipat Institute of Engineering & Technology, Panipat, Haryana, India                      |
| <b>Sandeep Kumar</b>               | Department of Information Technology, Panipat Institute of Engineering & Technology, Panipat, Haryana, India                      |
| <b>Shally</b>                      | Department of CSE-AIDS, Panipat Institute of Engineering and Technology, Samalkha, India  |
| <b>Vaishali Shende</b>             | Department of Artificial Intelligence, G. H. Rasoni College of Engineering, Nagpur, India   |

**CHAPTER 1****Development and Performance Enhancement of Machine Learning Based Approaches for Detection of Skin Diseases****Krupali Dhawale<sup>1,\*</sup> and A. R. Patil Bhagat<sup>1,\*</sup>**<sup>1</sup> *Department of Computer Technology, Yeshwantrao Chavan College of Engineering, Nagpur, India*

**Abstract:** The intricacy of dermatological illnesses like papulosquamous disorders makes diagnosing the human skin, the biggest organ in the body, frequently difficult. Conventional diagnostic techniques might include invasive muscle biopsies, which would be uncomfortable and burdensome for patients. Through the use of advanced machine learning algorithms, this research seeks to eliminate the necessity for intrusive operations. The suggested method looks to improve patient outcomes and streamline dermatological care by enabling early-stage, non-invasive, and accurate diagnosis through the analysis of several datasets of skin disorders. The purpose of this chapter is to examine novel, non-invasive diagnostic techniques for intricate dermatological problems, with an emphasis on papulosquamous disorders. The book chapter aims to offer insights for substituting effective, data-driven solutions for invasive biopsy procedures by utilizing cutting-edge machine learning techniques. Additionally, it looks at the difficulties in evaluating datasets on a variety of skin conditions. It emphasizes how artificial intelligence may improve patient outcomes, increase diagnostic precision, and revolutionize dermatological procedures.

**Keywords:** CNN, ML, Papulosquamous skin disorders, DL.

**INTRODUCTION**

The human skin is the largest part of our bodies, encompassing the dermis, the outermost layer of the lymphatic system, tissues beneath the skin, nerves, muscles, and blood vessels. Far beyond serving as a robust defence against a spectrum of threats, from germs, viruses, reactions, to bacterial and fungal illnesses, it exhibits a dynamic, transformative nature. This transformative quality enables the skin to adapt and influence its texture in response to the ever-changing

---

\* **Corresponding author Krupali Dhawale and A. R. Patil Bhagat:** Department of Computer Technology, Yeshwantrao Chavan College of Engineering, Nagpur, India;  
E-mails: krupali.acem@gmail.com, arbhagatpatil@gmail.com

interplay with external elements [1, 2]. In addition to serving as a strong barrier against viruses, bacteria, allergens, and fungal infections, the skin's outer layer also indicates the presence of these pathogens through typical signs of skin infections, such as itching, swelling, redness, and burning. A diverse set of conditions known as papulosquamous diseases is given major attention due to their high occurrences. Two distinct morphological features, the tissue reaction pattern and the inflammatory pattern, must be recognized and integrated in order to understand multiple skin biopsies. Clinical conditions, including erythematous, papular, squamous, and noninfectious lesions, include lichen planus, psoriasis, *Pityriasis rosea*, Pityriasis Rubra Pilaris (PRP), and many others. A few papulosquamous diseases, such as psoriasis, resemble many dermatological disorders because they have a wide range of clinical manifestations and appear to be a diagnostic dilemma for the clinician [3].

The skin condition known as psoriasis typically affects the knees, elbows, trunk, and head of hair, and causes a rash with itchy, scaly spots. There is no cure for psoriasis, a widespread chronic illness. It may hurt, disrupt sleep, and make it difficult to focus. The illness often flares up for a few weeks or months and then isn't present for a time. For those who are genetically predisposed to psoriasis, infections, burns, and several drugs are common triggers [1, 4].

Lichen planus emerges as an inflammatory papulosquamous condition that uniquely affects both the skin and mucous membranes. It predominantly targets areas like the skin, nails, and mucosal surfaces, while refraining from involving internal organs. Noteworthy is its heightened occurrence in women, because oral lichen planus has a higher risk of developing into oral cancer, and it requires special attention. The result illustrates the need for clinical classification in continuing surveillance. Unique characteristics such as saw-tooth rete ridges, atrophy, acanthosis, hyperorthokeratosis, and melanin incontinence are revealed by histopathological examination, providing important information for an accurate diagnosis and successful treatment. In this study [5], the usual preliminary appearance of *Pityriasis rosea* is an oval area on the face, chest, abdominal area, or back. Although this can occur at any age, it mainly appears in people between the ages of 10 and 35. In a period of ten weeks, it usually goes away on its own. The herald patch, a sizable, slightly elevated, scaly patch, usually appears first [1, 6]. Hyperkeratotic follicular papules, palmoplantar keratoderma, and salmon-colored, scaly confluent plaques with islands of sparing are the hallmarks of Pityriasis Rubra Pilaris (PRP), a rare inflammatory papulosquamous condition [1, 4, 6]. The difficulty in correctly distinguishing papulosquamous skin conditions lies in the multiple kinds of morphological signs and symptoms. These medical conditions are difficult to distinguish from one another due to similarities in appearance, which might result in wrong diagnoses. Thus, skin conditions have an

adverse effect on a person's mental, social, and quality of life. They also contribute to psychological stress for the family and have a detrimental effect on social and mental health. Considering the broad spectrum of Papulosquamous skin disorders' signs and symptoms and histological patterns, it's critical to identify the different kinds of lesions in order to provide effective treatment. In order to get within these limitations, we are providing a few machine learning-based methods for detecting papulosquamous skin conditions. The main goal is to evaluate the efficiency of the model compared to current dermatological evaluation methods and assess its performance using a range of criteria. The study's conclusions have significant implications, especially since they aim to increase the effectiveness and accuracy of dermatological diagnostic procedures and open the door for early detection of papulosquamous skin conditions [1, 5, 7].

The core purpose of this work is to overcome the problems and limitations by enabling the detection of various dermatological conditions from color, itching, papules, scaling, and family history. A challenging task due to the apparent resemblance among many skin conditions. It is a very difficult diagnostic dilemma for the clinician. In some cases, invasive muscle biopsy procedures are required to diagnose skin diseases, which can be burdensome for patients [2, 6, 7]. The aim of this research is to avoid the need for invasive muscle biopsy procedures for diagnosing Papulosquamous skin diseases. We propose the development of machine learning-based approaches for early-stage detection of these conditions.

The suggested model uses a wide range of skin images and an appearance-based Convolutional Neural Network (CNN) that can simultaneously detect numerous conditions of the skin in an effort to compensate for earlier limitations. The main objective is to fully assess the performance of the suggested model using a range of metrics and contrast it with current approaches. The proposed research has substantial implications for enhancing the accuracy and effectiveness of dermatological exams, which are crucial in the early detection of papulosquamous skin diseases.

## LITERATURE REVIEW

Several researchers have dedicated their efforts to the domain of skin disease detection and prediction, with notable contributions shown in Table 1:

Convolutional Neural Networks (CNN) and Long Short-Term Memory (LSTM) are two sophisticated deep learning algorithms that Aijaz *et al.* [6] and Moon *et al.* [8] developed in order to tackle the difficult job of psoriasis categorization. Their approach was revolutionary, exploring novel techniques for distinguishing between different forms of psoriasis by examining color and textural

**CHAPTER 2****Foundation of Data Science and Machine Learning in Healthcare****Jagvijay Singh<sup>1,\*</sup>, Anisha<sup>2</sup> and Roshni Jha<sup>2</sup>**<sup>1</sup> *Eduvate Consultancy Pvt. Ltd., Gr.Noida, U.P., India*<sup>2</sup> *Department of CSE-AIDS, Panipat Institute of Engineering and Technology, Samalkha, India*

**Abstract:** Data science and machine learning are revolutionizing medical systems by offering new paradigms using powerful solutions to address some of the most significant problems in healthcare. This chapter provides an overview of the fundamental principles of the groundbreaking technologies, including applications and utilization in healthcare. It will include data science basics such as exploratory analysis, acquisition, and preprocessing, intended for various data types in healthcare, such as Electronic Health Records and other medical records. Other factors, such as the conceptualization of new factor collections and reduction of algorithmic bias, enhancing the model's interpretability, and privacy frameworks, are critical before utilization by clinics. It offers disease diagnosis, treatment enhancement, and resource rations as instances of areas where data science and ML can bridge the data-market gap in healthcare. Other developments to promote the transformation include new ideas like federated learning, natural language processing, and real-time analytics. It emphasizes how data-based methodologies can radically change patient results and increase individualized procedures and operational effectiveness. Lastly, it will introduce the current topic with a conclusion of the AI development aspect in healthcare and the path that will shape the future of the sector.

**Keywords:** Artificial intelligence, Data science, Healthcare, Machine learning, Patient.

**INTRODUCTION**

Medical data use began in the 1960s when computers started processing patient data. Since then, medicine in general has been revolutionized by data science. Modern medical informatics began in 1965, when the National Library of Medicine introduced Medline, one of the first databases of biological literature. Data science is finally revolutionizing patient care *via* individualized therapies, predictive analytics, and optimized procedures. The U.S. healthcare system may

---

\* **Corresponding author Jagvijay Singh:** Eduvate Consultancy Pvt. Ltd., Gr. Noida, U.P., India;  
E-mail: jagvijaysingh2@gmail.com

potentially generate up to \$100 billion annually by implementing Big Data technologies, depending on how clinical operations are streamlined, costs are reduced, and patient outcomes are improved. One of the most important advantages of data science is the ability of the technologies to provide actionable insights that could improve patient outcomes. Large-scale healthcare information research has provided patterns and trends that make it easier to regulate resources, diagnose illnesses sooner, and optimize therapy [1].

The healthcare industry is currently in the process of experiencing an incredible transformation with the increasing role of data science and ML. These advanced technologies have managed to assist in addressing some of the most complex issues related to healthcare, disease detection, treatments, and resource usage. The insights gained from a collection of already existing medical data allow for better decision-making and more positive patient results. This collaboration between healthcare and technology may be defined as a new way of rationalizing, innovating, and thinking about how we can approach the issue of enhancing the industry's efficiency. In other words, data science represents the process of dealing with the enormous amount of structured and unstructured data with the aid of statistical analysis, predictive modeling, and data mining. ML may be seen as a form of artificial intelligence that aids a system in making forecasts or choices based on given information without having been programmed explicitly to do so. These two go hand-in-hand to help analyze and comprehend the enormous quantity of data generated by EHRs, wearables, imaging, and genomics, which is quickly growing unique for the healthcare industry [2].

The reason health care employs these technologies is that the amount of health care data is growing with the explosion of datasets produced by unprecedented advances in medical imaging, genomic sequencing, and telemedicine, and sophisticated analytical techniques have been developed. For instance, ML algorithms can be fed imaging data in order to conduct future scans to look for defects, such as tumors, with greater accuracy. Similarly, genomic data is these medical markers and machinery can be processed to identify specifically genetic markers associated with specific diseases of the day mark and function. The other components of data science and ML in health care are predictive analytics. These models can read patient data and see which patients are most likely to develop chronic diseases like diabetes and heart disease. Such early detection results in early treatment and less pressure on the health care system. It also has a positive impact on patients' quality of life. Predictive models make it easier to run hospitals in certain ways, including managing staffing effectively, deciding where to place the beds, and determining which equipment is most useful [2].

Despite the potential that these technologies hold, their integration into healthcare systems faces several challenges. For the scaling up of AI in this industry, some of the current issues, such as data privacy, algorithmic bias, and the environment, need to be addressed. Setting up frameworks that ensure patient safety and define the space of trust will be central to unlocking the full potential of data science and ML in Healthcare, as in the case of Healthcare being the foundation for the field of data science and ML, with the field being more than mere implanted devices influencing treatment and diagnosis, but actual innovation drivers influencing the way health is delivered and experienced. As such, with the continued development of this technology, and with the same circling out the existing gap between technologists, researchers, and clinicians, the shape and focus of healthcare will be more patient-tailored and accessible more than ever [3].

### **Health Data Types**

Big data and analytics-enabled healthcare utilizes an ever-expanding array of data sources to record different dimensions of patient care delivery and outcomes, serving as evidence to systematically underpin clinical and policy decision-making. Structured databases primarily consist of three main sources: patients' EHRs obtained from hospitals, healthcare systems, administrative insurance claim systems, or disease registries, and diagnostic test results. Structured databases are beneficial for multiple applications, each with different strengths and limitations [4].

### ***Clinical Trials***

The “Randomized Controlled Trial” (RCT) is the gold-standard method for evaluating the safety and efficacy of diagnostic tests, devices, biologics, and treatments before regulatory approval. Clinical trials assess therapies in specific patient groups, adhere to strict guidelines, and monitor outcomes over a defined period. Treatments given, predetermined clinical outcomes, symptoms reported by patients, evaluations by clinicians, precision diagnostics, genetic biomarkers, other measurable endpoints, and adverse occurrences are among the data items recorded. When compared to alternatives such as placebos or other medications, RCT datasets provide the most scientifically accurate evaluation of an intervention's effectiveness and toxicity because important variables are purposefully balanced across research arms utilizing random assignment and eligibility criteria. There is a chance that this internal validity will result in less generalizability and applicability. Because of this, accurately conveying benefits and risks to diverse real-world populations is difficult. Results from published trials often exaggerate efficacy when extrapolated. To supplement traditional efficacy results throughout the product lifetime, further information from

**CHAPTER 3****Genomics Data Analytics: An Innovative Approach to Precision Medicine****Sorabh Gupta<sup>1,\*</sup>, Rashmi Makkar<sup>1</sup> and Neha Bhatia<sup>1</sup>**<sup>1</sup> *Department of Information Technology, Panipat Institute of Engineering & Technology, Panipat, Haryana, India*

**Abstract:** Genomic medicine aims to build personalized strategies for making diagnostic or therapeutic decisions using patients' genomic information. The importance of genomic data analysis in precision medicine is enormous, with bioinformatics, data mining, machine learning, and blockchain technologies playing a key role in advancing personalized healthcare. These technologies make it easier to analyze, interpret, and use large genomic datasets to predict, diagnose, and treat diseases at the individual level. Genomic data analytics reveals the unidentified correlations among unseen designs and other understandings through the investigation of extensive data sets. Even though there are some problems in combining and manipulating different types of genomic data, full Electronic Health Records (EHRs) on big data infrastructures are a beneficial way to find genetic variants that can be used in personalized medicine and diagnosis. Personalized medicine, also known as precision medicine, represents a transformative approach to healthcare, customizing medical interventions based on the unique characteristics of individuals. Precision medicine promises better health outcomes through personalized treatment plans. This chapter outlines how new technologies and patient-centered care could help make the vision of precision medicine come true.

**Keywords:** Data analytics, Electronic health records, Genomics, Healthcare, Personalized medicine, Precision medicine.

**INTRODUCTION**

The advent of precision medicine and genomics is revolutionizing the healthcare landscape through tailoring therapies to specific patient characteristics, in contrast to the traditional universal approach. Genomics is the study of genes and how they interact with environmental and lifestyle factors. Information Technology (IT) holds pivotal importance by equipping the tools and infrastructure to analyze genomic data [1]. New developments in Machine Learning (ML), AI, and big data

\* **Corresponding author Sorabh Gupta:** Department of Information Technology, Panipat Institute of Engineering & Technology, Panipat, Haryana, India; E-mail: sorabhg2003@gmail.com

analytics find patterns in genomic and clinical data. These days, we can use Whole Exome Sequencing (WES), Whole Genome Sequencing (WGS), and targeted sequencing to identify genetic differences associated with disease. This makes precision medicine possible [2, 3]. These tools enable physicians to predict therapeutic outcomes considering genetic, lifestyle, and environmental factors [4]. Putting together Electronic Health Records (EHRs) and big data analytics reveals hidden connections between genomic and clinical datasets, advancing precision medicine.

Drawing from the human genome, personalized medicine identifies genetic variations that influence diseases such as cancer, diabetes, and cardiovascular conditions. Biomarkers help predict diseases and understand patient subgroups that are responsive to specific drugs. Owing to developments in genotyping, biochips, and SNPs (single-nucleotide polymorphisms), personalized medicine is now a reality, allowing for focused and precise therapies. High-throughput technology and big data analytics allow efficient analysis of large datasets, requiring advanced computational tools and methodologies. Personalized medicine focuses on delivering optimal treatment precisely when needed, leveraging genomic, behavioral, and environmental data. Despite the challenges, it enhances diagnostic accuracy, therapeutic effectiveness, and preventive healthcare [5, 6].

A branch of personalized medicine, *i.e.*, Precision Medicine, leverages genetic and molecular data to progress targeted remedies [7]. Advances in genomics, transcriptomics, proteomics, and metabolomics guide treatments using biomarkers, improving individualized care. Since the human genome was mapped in 2003, personalized medicine has expanded, aiming to prevent, diagnose, and manage diseases based on each patient's unique profile. Personalized medicine categorizes patients into subpopulations based on disease susceptibility or treatment response. Big data approaches improve accuracy but remain aspirational. Challenges include high costs and regulatory barriers, though ongoing research aims to cut drug development costs and improve healthcare outcomes [8]. ML algorithms process diverse datasets, including EHRs, genomic data, and wearable device inputs, to predict outcomes and recommend tailored treatments. By integrating big data tools and predictive analytics, personalized medicine provides unprecedented insights into individual care, revolutionizing global healthcare delivery [9].

## BACKGROUND

### Historical Development of Precision Medicine

The concept of precision medicine, which optimizes healthcare decisions, practices, and treatments for individual patients, has evolved considerably over the past decades. Precision medicine has its roots in late 20<sup>th</sup>-century pharmacogenomics, which studied how genetic variations affect drug responses [10]. As part of the Human Genome Project (HGP), the mapping of the entire human genome in 2003 was a major accomplishment that made it possible to find genetic markers that are associated with diseases and drug responses [11]. The next big steps include targeted cancer treatments, advances in genomic sequencing, and programs such as the 2015 U.S. Precision Medicine Initiative, which used genomics in medical care [12].

The identification of DNA and the genetic code at the turn of the century laid the scientific groundwork for individualized medicine. In the field of cancer treatment, genomic sequencing and diagnosis enable accurate cancer classification & targeted therapies, for example, HER2 and EGFR inhibitors, have been developed for specific genetic mutations [13]. Technological advances such as NGS and bioinformatics have accelerated biomarker identification and disease understanding [14]. Imatinib is a useful example as it targets the BCR-ABL tyrosine kinase in chronic myelogenous leukemia. Improvements in health Information Technology (IT), Especially Electronic Health Records (EHRs), have made it easier to use genetic information in clinical settings [15]. This has helped personalized medicine grow. EHRs store patient histories, test results, and other data critical for genomic research applications [16].

### Key Concepts in Genomics

Genomics, a subdivision of genetics, focuses on sequencing and analyzing genomes to understand gene structure, function, evolution, and mapping. Genomics provides foundational insights into biological processes and the genetic underpinnings of diseases, driving advances in personalized medicine and biotechnology. Key concepts in genomics include:

- **Genetic Variation:** Differences in DNA sequences among individuals affect disease susceptibility, drug responses, and interactions with environmental factors. Single-Nucleotide Polymorphisms (SNPs) and structural variations, such as insertions and deletions, are major sources of genetic diversity.

## Imaging Data Analysis in Precision Medicine

Sayali R. Tajane<sup>1,\*</sup> and Shivraj Guduri<sup>2</sup>

<sup>1</sup> Department of Computer Science Engineering, G.H. Raisoni College of Engineering, Nagpur, India

<sup>2</sup> Department of Artificial intelligence, G.H. Raisoni College of Engineering, Nagpur, India

**Abstract:** Precision medicine relies heavily on imaging data analysis because it enables precise diagnosis and treatment planning by extracting valuable information from medical images. Advanced techniques in data science and machine learning now enable faster and more precise assessments of MRI, CT, PET, and X-ray imaging modalities. Machine learning algorithms boost anomaly detection and classification while improving segmentation capabilities, enabling early disease detection, such as cancer and neurological disorders. Therapeutic treatment plans become more precise and comprehensive when genomic information is integrated with various imaging modalities.

**Keywords:** Deep learning, Ethical considerations, Imaging data analysis, Machine learning algorithms, Multi-modal imaging, Personalized healthcare, Precision medicine.

### INTRODUCTION

Being inherently non-invasive, medical imaging provides information about the biology and physiology of tissues and organs and has therefore always remained at the heart of modern medicine. With the advancement of precision medicine, the very usage of imaging data has transformed significantly, from just straightforward visual examination to a much more complicated data-driven method of analysis. Now, imaging data constitutes an input into personalized patient care, which is then further utilized in the formulation of individualized treatment and diagnostic strategies [1].

With the recent enhancement in imaging equipment like high-resolution MRI, CT, PET, and advanced nuclear imaging, large datasets have been produced. These

---

\* Corresponding author Sayali R. Tajane: Department of Computer Science Engineering, G.H. Raisoni College of Engineering, Nagpur, India; E-mail: tajne.sayali23@gmail.com

information-rich datasets, when interfaced with newer machine learning algorithms, facilitate the extraction of patterns and features beyond the perceptual capability of human radiologists. For example, imaging biomarkers derived from these datasets can provide information related to tumor heterogeneity, microvascular density, and metabolic activity. This also proves to be a very important factor in the diagnosis of diseases like cancer, heart conditions, and neurological disorders; however, it also helps predict the course of these diseases and assess therapeutic interventions [2].

Imaging data, several types, can have an added value in the field of precision medicine, provided that more clinical and molecular data (such as proteomics and genomics) are taken into consideration. Together, this joint examination therefore provides a much broader biological understanding of the illness mechanism and the development of tailored therapies. Imaging data analysis then enables adaptive and dynamic therapies that can be dynamically modified by real-time monitoring of the disease and treatment outcome [3].


In particular, this chapter describes the technical methods and resources that can support imaging data analysis within the domain of precision medicine. We study advanced methods in deep learning and machine learning that now permeate all aspects of predictive modeling, anomaly detection, and feature extraction. Convolutional Neural Networks (CNNs) stand out particularly as highly effective for a variety of tasks, including object detection, classification, and image segmentation. We then review multi-modal imaging data fusion, an integration of several different imaging modalities to increase diagnostic precision and thus provide a multifaceted viewpoint on patient health [4].

We continue below with some practical challenges of analyzing big imaging datasets, like computational burdens, the heterogeneity of data, and drawing up solid data pre-treatment pipelines. Then, we go into critical discussions about ethical concerns, such as algorithmic bias, data privacy, and fair opportunities for AI-based medical solutions. These challenges demonstrate how important it is to have a consistent set of directives and standards for the moral and effective analysis of imaging data [4].

The chapter ends with a discussion of anticipated trends and technological changes, such as explainable AI to foster trust between patients and healthcare practitioners, federated learning for decentralized data analyses, and quantum computing for enhanced power of analysis. Together, these trends stand to change the landscape of imaging data analysis [5].

## MACHINE LEARNING IN IMAGING DATA ANALYSIS

Machine Learning (ML), which allows for the extraction of useful information from very large and complex datasets, has truly revolutionized medical imaging. By employing more sophisticated algorithms and machine learning techniques, physicians can forecast how a disease may progress, properly diagnose patients, and plan better treatments. Below, the core areas of the machine learning application on imaging data processing are discussed in detail [6] (Fig. 1).



**Fig. (1).** The stepwise process for imaging data analysis is illustrated.

From “Deep learning approaches for multimodal imaging data analysis in precision oncology” by P. Zhao, R. Gupta, and M. L. Watson, 2024, IEEE Access, 13, 3456–3464 (<https://doi.org/10.1109/ACCESS.2024.3175031>); and “Advanced image processing techniques for precision medicine: A comprehensive review” by L. M. Zhao, T. M. King, and J. H. Kim, 2023, Proc. IEEE Int. Conf. Image Process., Barcelona, Spain, pp. 122–128. Adapted with permission.

### Image Segmentation

Segmentation represents a very significant phase in imaging data processing as it attempts to dissect an image into meaningful elements for the identification and

## CHAPTER 5

# Electronic Health Records (EHR) and Clinical Decision Support System

Shankar Gadve<sup>1</sup> and Goldi Soni<sup>1,\*</sup>

<sup>1</sup> Amity School of Engineering & Technology, Amity University, Chhattisgarh, Raipur, India

**Abstract:** Since it facilitates digitization and the creation of advanced solutions, information and communication technology, or ICT, has become essential to many aspects of society, including healthcare. The growing amount of patient data has sped up the implementation of digital health technology, like Electronic Health Records (EHRs). However, there are a number of significant issues with traditional EHR systems, such as the possibility of data loss, worries about the privacy and integrity of medical information, ineffective clinical record retrieval, and a lack of efficient communication between participating hospitals. Integrating blockchain technology into healthcare data management systems addresses existing limitations by providing a decentralized, secure, and efficient approach. The use of JavaScript-based smart contracts and platforms like Hyperledger Fabric and Composer facilitates the development of patient-centric designs that ensure data integrity, privacy, and interoperability, ultimately transforming healthcare delivery.

**Keywords:** Blockchain code, Blockchain technology, Concept of Ethereum, Electronic healthcare records, Patient-centric framework.

## INTRODUCTION

An increasing collection of data, or blocks, connected by cryptography is known as blockchain technology. Each block may contain a timestamp, exchange information, and a cryptographic hash of the block before it. Blockchain technology resists information manipulation. It refers to "a distributed, open data that can be efficiently and irrefutably stored between two peers." A shared network that adheres to a consistent rule for validating new blocks and enabling inter-node communication oversees the distributed record known as a blockchain. No block's data may be changed backwards once it has been recorded without changing all subsequent blocks, which requires network-wide consent.

---

\* **Corresponding author Goldi Soni:** Amity School of Engineering & Technology, Amity University, Chhattisgarh, Raipur, India; E-mail: gsoni@rpr.amity.edu.in

Blockchain appears to be secure by design, and the data is not unchangeable. The use of highly Byzantine distributed computing systems can lead to non-critical failures [1].

The society needs a stronger healthcare system because of the pandemic, and an improved healthcare system is essential. Given the daily occurrence of emergencies, casualties, and poor health, it is expected that diseases will be examined and treated. An assortment of clinical information about a patient's physical and mental well-being that has been compiled from multiple sources is called a health record. A patient's clinical history, evaluation, conclusion, therapy, lab test results, and checking reports are all included in their health record. Both manual and digital methods can be used to view these medical records [2].

The manual approach, which uses books and papers, is the traditional method used in the majority of emergency clinics to maintain their records. This approach has real drawbacks, such as the need for a large storage space and the difficulty of recovering records. Clinical record computerization has gained popularity in the modern period due to its ease of storage and retrieval, but the possibility of manipulation in the absence of identifiable evidence has grown to be a real worry. Another significant problem is the hidden keeping of patient data, since the patient may accuse the physician and the hospital of violating the confidentiality of their health records. Additionally, paper-based records are frequently insufficient, which leads to unnecessary repeat tests and prescriptions [3].

Blockchain, the innovation of things to come, impartially encouraged the financial transactions in cryptocurrencies by carefully disposing of the requirement for an administering authority or an administration to authenticate the transactions, which are based on transparency and trust.

According to Patrick *et al.* (2019), the South African public medical care division provides free and moderate medical services to South African people. The parts of private medical services are not commonly affordable and hence not open to most people. In South Africa, general medical services use blockchain technology. Consider the example accompanying situation mentioned in Fig. (1), an individual reports to a public emergency clinic for treatment. By and large, a medical services professional will collect patients' information. In the blockchain, the patient's information is incorporated afterward [4].

With the patient's medical healthcare information as the main set of transactions, this is called a block. This section carries information about patients typified within the hash. After that, the doctor diagnoses the patients in a similar hospital and gives the healing prescription to the patients. These exchanges processed by the specialist are consolidated in the blockchain, just like block 2, which relates to

the hash algorithm and with the header of a hash of block1. The role of block 3 is that the pharmacist processes the transaction and encapsulates it when the patient obtains the drug [5].




Fig. (1). An example of how blockchain technology could be used in a healthcare system.

In such cases, blockchain can have an audit process where every transaction is safe, *i.e.*, no one can change or fix it, and it can also be followed with timestamp data. The above situation can have possibilities to enhance accountability in different ways, which can be achieved by utilizing blockchain.

## BACKGROUND

This section presents recent research on these subjects. Applications of blockchain technology in the medical field have been reported. Authenticity, security, sharing, and privacy of data have all been addressed at various levels in blockchain-active healthcare use cases [4, 5] that have emerged to show the relevance of blockchain methodology in the healthcare industry. These issues have been brought about by the development of blockchain technology. Hathiya *et al.* [4] introduced the Automated Validation Internet Security Protocol and Application (AVISPA) for secure EHR, an improved location- and biometric-based access control system. Huang *et al.* [6] investigated a user-centric method for validation and integrity, but its scalability was severely limited by sensor limitations, which was further presented by Fan *et al.*

MedBlock, a healthcare information system, uses distributed ledgers to facilitate effective access and offer a better consensus mechanism. The dependability and traceability of medical data may be attested to by Wang and Song's (24) [7]

## CHAPTER 6

## Pharmacogenomics and Drug Development

Ragini Vishwakarma<sup>1</sup> and Smriti Mall<sup>1,\*</sup>

<sup>1</sup> *Molecular Plant Pathology Laboratory Department of Botany, Deen Dayal Upadhyaya Gorakhpur University, Gorakhpur, UP-273009, India*

**Abstract:** Pharmacogenomics, essentially based on how genetic differences influence a person's response to drugs, has emerged as a cornerstone of personalized medicine. By integrating genomic data into drug discovery and development, pharmacogenomics provides enhanced therapeutic efficacy and minimized adverse drug reactions. This approach enables the identification of biomarkers for patient stratification, optimizes clinical trial design, and accelerates the development of targeted therapies. Current advanced genomic techniques, including next-generation sequencing and CRISPR-Cas9, have further revolutionized the field, enabling precise gene-drug interaction mapping and functional validation. Pharmacogenomics also plays a significant role in the reuse for a new purpose of existing medicines and in forecasting far-off effects, which can lead to lower cost input and take less time in the development of a new drug. However, despite these advantages, challenges such as the complicated data, ethical issues, and in of these issues into clinical practice continue to pose obstacles to broader adoption. This chapter explores the transformative impact of pharmacogenomics on drug discovery, highlighting key breakthroughs, emerging technologies, and future directions for this dynamic field.

**Keywords:** Pharmacogenomics, Patient stratification, Emerging technologies, Drug, Patient.

### INTRODUCTION

The term “pharmacogenetics” was first coined by Friedrich Vogel in 1959, although the importance of hereditary genetic factors that affect clinical results to xenobiotics had been recognized way earlier [1]. The field of pharmacogenomics explores the effects of genes on drug response. The terminology includes pharmacology as well as genomics to help physicians refer safe and appropriate drugs to patients with respect to their genetic framework [2]. On the other hand, Pharmacodynamics is related to the study of physiological, molecular, and biochemical effects of drugs, which includes chemical interactions, receptor binding activity, and post-receptor impact [3]. One of the best examples of

\* **Corresponding author Smriti Mall:** Molecular Plant Pathology Laboratory Department of Botany, Deen Dayal Upadhyaya Gorakhpur University, Gorakhpur, UP-273009, India; E-mail: smriti.bot@ddugu.ac.in


pharmacogenomics in present practice is the use of the antiretroviral drug Abacavir for HIV/AIDS treatment. Approximately 5% of the current population shows a severe hypersensitivity reaction towards this drug, which in certain cases can be life-threatening [4].

Pharmacogenomics is a major constituent of genomic medicine. It utilizes patients' genetic information to accommodate drug selection in clinical management. The main aim of pharmacogenomics is to achieve more specific use of available drugs [5]. This is mainly achieved by integrating details of the test subject's genetic constitution in drug therapy to design much safer and more effective therapy methods. The methods mainly employed in genetic analysis are mass spectrometry, kinetic-fluorescence detection, high-performance liquid chromatography, and pyrosequencing [6]. Pharmacogenomics plays an essential role in drug designing, treatment, and development, focusing on its response to genes and the complex genetic system that influences it [7].


This chapter gives a comprehensive overview of pharmacogenomics, its role in drug development, drug response, influence of genetic variability, pharmacogenomic biomarkers, applications of pharmacogenomics in drug development, and its challenges.

## **PRESENT SCENARIO IN DRUG DISCOVERY AND DEVELOPMENT**


The appropriate usage and efficiency of a particular drug is analyzed with respect to firm regulation and strict guidelines before it is approved to be advertised for public use [8]. Creation of a new drug requires huge capital investment, human resources, and technological expertise in addition to the implementation of regulations for drug testing and manufacturing protocols. All of these factors sum up to cause an increase in the cost of drug development and research [9]. The total cost input for drug development is significantly high, with an average of 403 million US dollars (2000 dollars) per drug. The high financial input leads to termination of medical trials in phase II and III since enormous resources have already been expended [10]. A considerable number of patients are prescribed medications that are either ineffective or dangerous on an individual scale. Similar challenges persist not only in the development of new drugs but also in prescribed medications, wherein the drug is either inefficient or causes adverse effects in certain patient subgroups [11]. Interestingly, various examples where clinically significant variation in drug activity is associated with genetic factors, even after approval and marketing of the drug for several decades (Fig. 1). It signifies the necessity for appropriate dose recommendations for such drugs in case of patients with external or internal determinants to minimize the disturbing effects of drug reactions [12].




1. Abacavir  
Molecular Formula:  $C_{14}H_{18}N_6O$




2. Boceprevir  
Molecular Formula:  $C_{27}H_{45}N_5O_5$




3. Metoprolol  
Molecular Formula:  $C_{15}H_{25}NO_3$




4. Clopidogrel  
Molecular Formula:  $C_{16}H_{16}ClNO_2S$




5. Cevimeline  
Molecular Formula:  $C_{10}H_{17}NOS$




6. Dronabinol  
Molecular Formula:  $C_{21}H_{30}O_2$



7. Warfarin  
Molecular Formula:  $C_{19}H_{16}O_4$



8. Atorvastatin  
Molecular Formula:  $C_{33}H_{35}FN_2O_5$



9. Carbamazepine  
Molecular Formula:  $C_{15}H_{12}N_2O$

**CHAPTER 7****Predictive Modeling and Patient Stratification****Krupali Dhawale<sup>1\*</sup>, Dhananjay Bhagat<sup>2</sup> and Parul Dubey<sup>3</sup>**

<sup>1</sup> Department of Computer Technology, Yeshwantrao Chavan College of Engineering, Nagpur, India

<sup>2</sup> Department of Computer Engineering and Technology, School of Computer Science and Engineering, Dr. Vishwanath Karad, MIT World Peace University, Pune, India

<sup>3</sup> Symbiosis Institute of Technology, Nagpur Campus, Symbiosis International (Deemed University), Pune, India

**Abstract:** Precision healthcare has ushered in a new era of medicine where preventative measures and therapies are tailored to each patient's unique genetic, environmental, and lifestyle characteristics. Interdisciplinary cooperation, which integrates the knowledge of genetics, AI, bioinformatics, clinical research, and social sciences, is essential to this revolution. This chapter explores how big data analytics, predictive modeling, and personalized biotechnologies might work together to revolutionize patient care, highlighting the synergy between these disparate domains. It also discusses the particular difficulties of putting precision healthcare into practice, such as moral conundrums, data security, and fair access. This chapter provides a forward-looking view of the potential of interdisciplinary approaches to transform healthcare into a truly patient-centered model through intriguing case studies and upcoming trends.

**Keywords:** Healthcare Analytics, Machine Learning in Medicine, Predictive Modeling, Patient Stratification.

**INTRODUCTION: PRECISION MEDICINE (TRANSFORMING HEALTHCARE)**

In the healthcare industry, predictive modeling is the process of analyzing past and present data using sophisticated statistical methods and machine learning algorithms to forecast future patient outcomes. To develop well-informed forecasts about individual or neighborhood health scenarios, this entails locating relationships, associations, and trends across intricate healthcare information. In the medical field, predictive modeling plays a crucial role in patient stratification by combining sophisticated statistical methods with machine learning to evaluate

---

\* **Corresponding author Krupali Dhawale:** Department of Artificial Intelligence, G. H. Raisoni College of Engineering, Nagpur; E-mail: krupali.aceem@gmail.com

patient data and forecast future health outcomes. Through this method, patients are divided into smaller groups according to common risk factors, medical problems, or anticipated treatment outcomes. Predictive models find trends that inform healthcare decisions by looking at data sources such as genetic information, electronic health records, and behavioural patterns. Forecasting the onset of chronic conditions like diabetes or hypertension, creating individualized treatment regimens, and identifying patients at risk of readmission to the hospital are some of the main uses. Patient stratification and predictive modeling work together to provide proactive care, efficient use of resources, and better, individually tailored health outcomes.

Big data analytics has opened up previously unheard-of possibilities for processing enormous volumes of health-related data, from behavioural patterns to genomic sequences. Using this information, predictive modeling forecasts treatment results, foresees disease risks, and improves healthcare delivery. When used in tandem, these resources provide for a flexible strategy for identifying individuals at high risk, tailoring therapies, and enhancing long-term health results. The smooth cooperation of interdisciplinary teams is essential to precision healthcare success. It takes collaboration amongst geneticists, data scientists, doctors, and social scientists to incorporate knowledge from their specialized disciplines into a comprehensive healthcare plan. This cooperative strategy not only speeds up research but also guarantees that developments tackle practical patient care issues.

### **Patient Stratification Overview**

A key procedure in modern healthcare is patient stratification, which divides patients into discrete categories according to variables like risk profiles, disease stages, and demographic traits. Healthcare professionals can see trends and customize care to meet the unique requirements of each group thanks to this classification. Physicians can create more accurate, customized care regimens that address the particular health issues that each subgroup faces by classifying patients based on similar characteristics such as genetic predispositions, lifestyle choices, or concomitant diseases. Patient stratification's main goal is to increase the efficacy of healthcare interventions by making sure that patients receive the best care possible given their unique risk factors or medical history. For example, patients with a higher risk of chronic condition problems may receive more intense care, whereas individuals with a lower risk may receive routine checkups or preventative care. Clinical results are greatly enhanced by this degree of personalization, which also encourages a more patient-centered treatment strategy. Stratification not only enhances patient care but also helps to maximize healthcare resources. Reducing needless treatments for low-risk patients allows for improved

distribution of healthcare services and cost savings by concentrating attention and resources on high-risk individuals. Patient stratification, therefore, promotes a more effective, sustainable, and just healthcare system in addition to supporting the implementation of precision medicine.

Predictive modeling is enabling accurate, proactive, and individualized care for patients, which is transforming the healthcare industry. By detecting illnesses, including cancer, diabetes, and heart disease, at the phases when interventions are most effective, this method improves early illness diagnosis. Probabilistic algorithms find unconscious trends in clinical data analysis, permitting prompt therapy and precise diagnosis. Predictive models also help customized medicine by customizing treatments to meet the needs of each patient, such as pharmacogenomics to assess a drug's efficacy [1]. Through the identification of high-risk patients, the reduction of needless hospitalizations, and the simplification of care delivery, these models help maximize resource allocation. They are also essential for managing chronic diseases, predicting flare-ups or disease progression for illnesses like rheumatoid arthritis and asthma [2]. When combined, these skills enable healthcare systems to provide patient-centered, economical, and effective care.

### **Related Work**

The significant advancements in technology and the industrial revolution have led to the widespread use of Artificial Intelligence (AI) [1]. In analyzing intricate patterns, Machine Learning (ML) systems have demonstrated remarkable success (Murdoch *et al.*, 2018). The expanding significance of explainable artificial intelligence (XAI) and its applications in healthcare is revealed by a thorough analysis of the literature in the areas of Machine Learning (ML) interpretability and predictive modeling. Di Noia *et al.* (2019) investigated genetic optimization and supervised machine learning methods for forecasting occupational disease risks, highlighting how these methods could enhance healthcare management and decision-making. Similar to this, Doshi-Velez and Kim (2017) and Du *et al.* (2018) address the necessity of interpretability in machine learning models and provide a road map for creating exacting interpretability methods that guarantee medical practitioners may have faith in predictions made by machines [2]. For real-world healthcare applications, it is essential to strike a balance between interpretability and model accuracy, as their work demonstrates. In reference to the healthcare industry, studies [3, 4] have highlighted how transparent models might improve clinical decision-making and patient trust by concentrating on the interpretability of machine learning-based models specifically for predicting hypertension. Endert *et al.* (2017) address the combination of visual analytics and machine learning, offering strategies to enhance the interpretability of intricate

**CHAPTER 8****Ethical and Regulatory Considerations for Precision Medicine****Pranali Dhawas<sup>1,\*</sup>, Mangala Madankar<sup>2</sup>, Vaishali Shende<sup>1</sup> and Shruti Thakur<sup>2</sup>**<sup>1</sup> Department of Artificial Intelligence, G. H. Rasoni College of Engineering, Nagpur, India<sup>2</sup> Department of Computer Science & Engineering, G. H. Rasoni College of Engineering, Nagpur, India

**Abstract:** By matching medical care to specific characteristics, precision medicine helps everyone receive the best treatment results based on their genetics and life situations. Pharmacogenomics and cancer genetics show great potential, but their development creates serious ethical problems. We will study ethical and regulatory problems of precision medicine through its impact on patient consent rights, as well as privacy concerns and biases against certain groups. Advanced technologies push precision medicine forward, but create problems when healthcare data lacks variety and threatens wider healthcare inequalities. When genetic data reveals patient risks without environmental factors in place, it creates ethical problems that may lead to unfair labeling. People wonder if everyone will get equal chances to use precision medicine because it costs too much money. This chapter shows why healthcare needs more research to ensure precision medicine is used properly in medical practice and keeps ethics such as patients' right to choose and equal healthcare access for all.

**Keywords:** Ethical considerations, Genetic data, Health disparities, Informed consent, Pharmacogenomics, Precision medicine.

**INTRODUCTION TO PRECISION MEDICINE**

Healthcare advances when medical programs and treatments are adjusted specifically to match an individual's unique qualities. By matching all patient information, including genetic traits and personal behaviors, with their environment, precision medicine enables doctors to provide better targeted medical care. By looking at the molecular structure of diseases, doctors can now select treatments that will work best for individual patients instead of giving every patient the same drug, as shown in Fig. (1). Doctors use NGS technology with artificial intelligence to analyze many possible health factors through bioinforma-

---

\* **Corresponding author Pranali Dhawas:** Department of Artificial Intelligence, G. H. Rasoni College of Engineering, Nagpur, India; E-mails: pranalidhawas10@gmail.com

tics and multi-omics studies. These systems help scientists analyze large medical datasets that combine genetic data with protein and metabolic information about a patient, as shown in Fig. (2).




Fig. (1). Traditional way of treatment without using precision medicine.




Fig. (2). Treatment using precision medicine.

## Historical Evolution and Key Advancements

The present concept of precision medicine extends previous principles behind personalized medicine, even though many people confuse the terms. Precision medicine takes individual care to new heights through its focus on medical science instead of traditional person-focused treatment.

### Key milestones in its evolution include:

***The Human Genome Project (1990-2003):*** The project on DNA understanding led scientists toward major breakthroughs in disease gene discovery. The research identified base factors that enable physicians to create individualized therapies for medical disorders.

***Advent of Next-Generation Sequencing (NGS):*** The 2000s featured a breakthrough in genomics research, which lowered both the costs and requirements for whole genome sequencing through NGS technology advancements. Next-generation technology simplified genome usage in medical diagnostic assessments.

***Introduction of Multi-Omics Technologies:*** Through their work in multiple omic fields, researchers developed an all-encompassing understanding of disease processes. Our ability to combine multiple diagnostic tests enables us to produce improved healthcare solutions that benefit cancer patients alongside people with heart diseases or brain conditions.

***Cancer Research and Targeted Therapies:*** The field of oncology introduced personalized medicine through drug therapies. Herceptin is designed for breast cancer patients having HER2-positive cells, while Gleevec targets chronic myeloid leukemia patients.

***Data-Driven Advances:*** Following advancements in big data analysis with artificial intelligence technology, healthcare providers can detect risks early during disease progression and anticipate upcoming medical conditions.

***CRISPR and Gene Editing Technologies:*** Through the direct application of CRISPR techniques, scientists accelerate precision medicine by correcting genetic mutations.

Precision medicine has evolved from its origins by combining genetic science with artificial intelligence techniques to create a comprehensive interdisciplinary healthcare research field. Genomics technology allows medical advances by enabling two main practices: personalized drug therapy and artificial intelligence tool development.

## Implementing Challenges and Best Practices in Precision Medicine

Neha Bhatia<sup>1,\*</sup>, Suman Kumari<sup>1</sup> and Sandeep Kumar<sup>1</sup>

<sup>1</sup> Department of Information Technology, Panipat Institute of Engineering & Technology, Panipat, Haryana, India

**Abstract:** Precision medicine is an advancement of the traditional medication system. It has taken a drastic change in the healthcare sector. This arena has proved to be most beneficial in the treatment related to oncology, but besides that, precision medicine is useful in treating other diseases too, such as various infectious diseases, obesity, chronic diseases, and cardiovascular diseases. This concept of precision medicine has outperformed during the COVID-19 pandemic by evolving several remedies and adjudicating the effectiveness of diseases. While implementing the concept, there are many challenges faced. In this book chapter, a comprehension of all the challenges faced and their proposed solutions during the practice of precision medicine is discussed. In the latter part, various best practices followed while implementing precision medicine are also elaborated. Integration of technologies such as artificial intelligence, machine learning, and data science during application is also discovered.

**Keywords:** AI, Challenges, Data science, ML, Precision medicine, Practices.

### INTRODUCTION

This trend of precision medicine has been ignited by new advances in the understanding of complex relations between health and diseases. This term is typically used to refer to hope for the goal of identifying and targeting extremely precise biological changes like certain deviations in gene structure, regulation, transcription, or post-transcription molecular pathways, though medicine arguably always was intended to be precise [1]. Therefore, patients with similar symptoms or signs, or with a tumor that is histologically similar, could be stratified into subgroups with different but very specific molecular defects that require different treatments. So, the promise of precision medicine is that a better outcome and more personalized treatment will follow from a deeper understanding of individual data. There is hope for this strategy.

---

\* Corresponding author Neha Bhatia: Department of Information Technology, Panipat Institute of Engineering & Technology, Panipat, Haryana, India; E-mail: neha.20july@gmail.com

Precision medicine has transformed the healthcare system by offering individually-tailored drugs, based upon the disease-causing defect, genetic makeup of the patient, and lifestyle, to deliver high-quality care with fewer adverse effects. Results have been most promising in oncology, chronic diseases, and infectious diseases, and yield optimal patient outcomes with minimal adverse effects. However, precision medicine is still fraught with technical, financial, regulatory, ethical, and infrastructural issues.

Most countries of the world have started genomic medicine projects with a view to making precision medicine the mainstream practice of healthcare, like the UK, the USA, and India. Still, shifting the paradigm of the conventional one-size-fits-all medicine into personal treatment models poses challenges [2]. The chapter describes major challenges faced while implementing precision medicine and its solutions.

**CHALLENGES IN PRECISION MEDICINE**

There are many challenges faced while implementing precision medicine [3]. These are mentioned below (Fig. 1):




Fig. (1). Challenges in Precision Medicine [4].

- Data Management and Big Data Challenges
- Financial and Economic Challenges
- Workforce and Training Limitations
- Regulatory and Ethical Challenges
- Infrastructure and Implementation Barriers
- Identifying distinct patient groupings and subgroups
- Including several morbidities
- Obtaining real-time data

## **Data Management and Big Data Challenges**

### ***Volume and Complexity of Data***

One of the key challenges in precision medicine is dealing with the humongous genomic and clinical data that sequencing technologies, medical imaging, wearable devices, and EHRs throw at us. Managing and analyzing these complex datasets requires very advanced computational infrastructures, advanced machine learning models, and significant bioinformatics knowledge.

Furthermore, genomic datasets contain heterogeneous data formats, which makes it tough to integrate information across various stages. The absence of uniform data collection methodologies increases the challenges of creating complete patient profiles.

### ***Data Storage and Security***

Genomic data processing requires storage facilities with high data security and privacy. Since genetic information is sensitive and unique, there is a possibility of misuse of the same by unauthorized parties such as insurers, employees, and so on. The existing encryption methods cannot fully eliminate the risk of data breach [4].

Healthcare professionals must fulfill the rigorous data privacy regulations as per GDPR in Europe and HIPAA in the United States, which impede the inter-institutional data sharing. Cloud storage can be advantageous, but it again raises concerns about data accessibility and control.

### ***Data Interpretation Challenges***

The understanding of genomic data is still a major challenge despite modern sequencing technology. The discovery of disease-related genetic variants is not necessarily converted into clinically useful information [5]. Moreover, different laboratories give different interpretations to the same genetic information, which causes discrepancies in the diagnosis and then the treatment.

## Precision Medicine: Improving Healthcare with Data Science and Machine Learning

Prashant Khobragade<sup>1,\*</sup>, Ashwini Yerlekar<sup>2</sup>, Abhijit Titarmare<sup>3</sup>, Payal Ghutke<sup>4</sup>, Neha Purohit<sup>5</sup>, Anand Babu Kotta<sup>6</sup> and Praveen Kumar Dhankar<sup>7</sup>

<sup>1</sup> Department of Computer Science and Engineering, G. H. Raisoni College of Engineering, Nagpur, India

<sup>2</sup> Department of CSE (AI&ML), S. B. Jain Institute of Technology, Management and Research, Nagpur, India

<sup>3</sup> Department of Electronics and Telecommunication Engineering, G. H. Raisoni College of Engineering, Nagpur, India

<sup>4</sup> Department of Electronics Engineering, G. H. Raisoni College of Engineering, Nagpur, India

<sup>5</sup> Department of Computer Science and Engineering, G. H. Raisoni College of Engineering, Nagpur, India

<sup>6</sup> Department of Mechanical Engineering, G. H. Raisoni College of Engineering, Nagpur, India

<sup>7</sup> Symbiosis Institute of Technology, Nagpur Campus, Symbiosis International (Deemed University), Pune, India

**Abstract:** Precision medicine is a huge step forward in healthcare because it focuses on making personalised treatment plans for each person by looking at their genes, their surroundings, and the decisions they make in their daily lives. Unlike the old “one-size-fits-all” method, precision medicine uses data science and Machine Learning (ML) to deal with the different types of diseases, the different ways that drugs work, and the complicated health data of each patient. Researchers and doctors have been able to find trends in genetic, clinical, and imaging datasets by combining big data analytics, prediction modelling, and advanced machine learning methods. This has led to more accurate diagnosis, analysis, and treatment plans. This article discusses the significance of machine learning approaches like Support Vector Machines (SVM), Random Forests, Neural Networks, and grouping algorithms for the evaluation of large organic datasets. Those techniques assist in identifying biomarkers, projecting treatment outcomes, and enhancing therapeutic processes through simplicity. A case study in cancer illustrates how ML models can be used to predict how patients will respond to personalised treatments, find out genetic markers related to drug resistance, and make sure that every patient receives the best treatment available. New kinds of illnesses discovered *via* precision medicine applications enable clinicians to create more targeted and successful treatment procedures. Precision medicine has great capability; its implementation is difficult due to problems like record protection, the requirement of

\* Corresponding author Prashant Khobragade: Department of Computer Science and Engineering, G. H. Raisoni College of Engineering, Nagpur, India; E-mail: prashant.khobragade@raisoni.net

ethical AI models, and the incapacity of healthcare structures to engage with one another. Data scientists, medical professionals, legislators, and regulatory authorities must cooperate to get past these issues.

**Keywords:** Biomarker discovery, Data science, Machine learning, Precision medicine, Personalized healthcare, Predictive modelling.

## INTRODUCTION

Precision medicine is changing the way healthcare is provided by making it possible to customise treatment plans for each patient based on their unique needs. To forecast and enhance patient outcomes, precision medicine aggregates lifestyle, environmental, and genetic data. This is not the case with the conventional “one-size-fits-all” paradigm of medical therapy, which does not often consider how differently various groups of individuals react to treatment [1]. By concentrating on specific groups of patients or even single individuals, this new kind of thinking seeks to make assessments more accurate, treatments more successful, and side effects less probable.

Modern healthcare generates a great volume of data from genomics sequences, Electronic Health Records (EHRs), imaging data, and real-time patient monitoring *via* smart devices. Precision medicine, that is, medical treatment catered to each individual's DNA information, features, and behaviour, as shown in Fig. (1). This approach lowers adverse effects and makes treatments more successful, therefore benefiting patients. This improves patient satisfaction and outcomes for general healthcare. Advanced analytic methods are necessary to extract relevant information from this complex and many data sources. These issues are being resolved increasingly using ML algorithms, which are well-known for their ability to identify patterns and provide forecasts from large datasets. Precision medicine nowadays incorporates ML extensively [2]. It is used to identify biomarkers, categorise patients, forecast illness progression, and ensure that every patient receives optimal therapy. Precision medicine has a lot of potential, but it also has a lot of problems. Widespread use is hard to achieve because diseases are not all the same, patient data is complicated, and different data sources need to be brought together. Concerns about data protection, bias in machine learning models, and fair access to precision medicine must also be taken into account. To solve these problems, healthcare workers, data scientists, and lawmakers need to work together across disciplines.




Fig. (1). Overview of precision medicine and its beneficiaries.

The research under review highlights how fresh applications of machine learning and deep learning could improve healthcare tools and tailored treatments. In paediatric critical care units, hybrid deep learning models improve occlusion segmentation. In critical care environments, this improves the dependability and precision of patient tracking [1]. Using heterogeneous network representation learning and contrastive learning, another investigation investigates which pharmacological combinations might be most beneficial together. This approach allows improved drug development and tailored therapies by combining many biological facts [2]. In digital pathology, a novel method of normalising Haematoxylin and Eosin (H&E) marked slides guarantees homogeneity of all files. This promotes the interconnections across packages related to computer pathology [3]. A facts-centric deep learning model for breast cancer diagnosis using dual-view sonography shows higher diagnostic accuracy by means of combining multi-view images and improved statistics preparation strategies. This gives an artificial intelligence-driven approach to early cancer detection [4]. Analysing how individualised remedies are provided in family exercise enables one to better understand how exceptional people see their use. This raises ethical and useful resource-associated problems as well as requires strategies that include all people to use in primary care [5]. In conclusion, an evaluation of polygenic threat ratings appears at their effectiveness for screening and risk category. It addresses their ability for customised therapy in addition to how they may help with issues such as population genetic variants and facts integration [6]. These

## Deep Learning Models for DR Prediction: A Comparative Analysis of CNN, RNN, and Ensemble Methods

R. S. M. Lakshmi Patibandla<sup>1,\*</sup>, B. Tarakeswara Rao<sup>2</sup> and Ramakrishna Murthy Malla<sup>3</sup>

<sup>1</sup> Department of CSE, Koneru Lakshmaiah Education Foundation, Guntur, Andhra Pradesh, India

<sup>2</sup> Department of CSE, KKR & KSR Institute of Technology and Sciences, Guntur, Andhra Pradesh, India

<sup>3</sup> Department of CSE, Anil Neerukonda Institute of Technology and Sciences, Visakhapatnam, Andhra Pradesh, India

**Abstract:** Diabetic Retinopathy (DR) poses a major hazard to global public health, causing considerable vision loss if left concealed. Deep learning algorithms have emerged as capable tools for recovering the accuracy of DR analysis and prediction. This chapter explores the potential of deep learning in enhancing predictive accuracy for DR, reviewing modern advancements and prominent key challenges, and future directions. Researchers inspect diverse deep learning architectures engaged for DR prediction, together with Convolutional Neural Networks (CNNs), Recurrent Neural Networks (RNNs), and ensemble methods. The authors attribute the underperformance of deep learning in DR prediction to some collision aspects such as data quality, interpretability, and ethical issues. Finally, the authors suggest a host of elucidatory opportunities and support Investigative Restorative practices as well as Team-Based Care for improved DR management.

**KEYWORDS:** Convolutional Neural Networks (CNNs), Diabetic Retinopathy (DR), Deep learning, Ensemble methods, Predictive medicine, Recurrent Neural Networks (RNNs).

### INTRODUCTION

Millions of people all over the world suffer from diabetic retinopathy, an ancient and insidious disease. Diabetes-related DR damages the blood vessels in the retina, which is a tissue that lines the rear of the eye and serves as light-sensitive tissue. This stealthy disease is the leading cause of blindness in adults ages 20 to

---

\* Corresponding author R. S. M. Lakshmi Patibandla: Department of CSE, Koneru Lakshmaiah Education Foundation, Guntur, Andhra Pradesh, India; E-mail: patibandla.lakshmi@gmail.com

74 because it often creeps up unnoticed and causes no symptoms until it's far along. The numbers paint a sobering picture: some 4.2 million of the nearly 34 million people with DR have advanced stages that could lead to blindness. Moreover, the World Health Organisation estimates that this disease has already taken 2.85 million lives. DR has far-reaching implications beyond individual suffering. It is one of the leading causes of blindness globally, in which millions lose their sight and ability to work or lead a fulfilling life. The economic burden is a heavy one and weighs down on health care systems through costs in screening, treatment, and rehabilitation of vision. It is the social impact that has far worse effects of dependency on others, loss of employment leading to a lower quality of life, which in turn contributes significantly towards ruining people's lives as individuals and their families and into societies [1 - 3].

However, there is still optimism; DR is largely curable and preventable because it requires early identification and treatment. Investing in health workers, having easily available screening programs, and promoting effective diabetes care can reverse the consequences of the disease on public health. Allowing researchers to work together will help millions of people keep their sight for a lifetime and have a better future for everyone. Although early detection is essential for preventing vision loss, many people are at risk because present diagnostic techniques for DR are difficult to use. The traditional approaches usually cannot capture all the subtleties of this condition. The traditional retinal examination's subjective character is one of its main drawbacks. These tests are performed based only on the optometrist's visual assessment, which may introduce errors or fail to detect small signs of early-stage DR. This also leads to geographical variations in diagnosis when many areas lack adequately trained personnel, making certain populations go undiagnosed until their conditions aggravate further. Additionally, manual grading of retinal images, which consumes time and effort, is another common feature in older methods. This may cause irreparable visual loss due to delays in diagnosis and treatment. Additionally, inter-observer heterogeneity in manual grading might impair the consistency and accuracy of diagnoses [4].

The limitations go beyond what is true or easily available. Patients and health care providers do not know where DR is headed because traditional methods cannot forecast disease progression. Thus, this interferes with proactive approaches to disease management and personalized treatments. There are serious issues with the present DR diagnosis and prediction strategies. Subjectivity, limited access, time constraints, and poor predictability lead to delayed diagnosis or missed opportunities for intervention, among other factors. New strategies that prioritize accuracy, accessibility, and the potential for future disease progression are needed to overcome these hurdles while keeping an invaluable vision gift for millions of diabetic people. Deep learning seems a glimmer of hope as the flaws in conventional methods become more obvious [5]. The potential of this powerful

branch of AI, inspired by the complex connections found in the human brain, to revolutionize healthcare, specifically in relation to DR, is very high.

Deep learning algorithms are particularly good when it comes to analyzing complicated data like retinal images. Through training with large image datasets, these algorithms can extract intricate features and patterns that may not be discernible by the human eye automatically. They therefore excel at spotting early symptoms of DR even before they start manifesting themselves. Additionally, deep learning models have higher information processing speeds compared to humans, thus enabling them to analyze large-scale data sets automatically and efficiently. As a result, this creates opportunities for extensive screening initiatives that can benefit disadvantaged communities and shorten diagnostic turnaround times. The importance of their potential influence on DR prediction lies in these algorithms' capacity of learning from different data sets that improve their accuracy and make patient-specific risk assessments possible. There are still more breakthroughs coming. Deep learning models also change over time as they are exposed to new data feeds. Due to their continuing education, they can stay on top of the ever-changing DR field and perhaps even predict its direction more accurately. This knowledge, if applied by medical personnel, could lead to improved customization of interventions and treatment plans that could save millions from sightlessness. The use of deep learning has brought a new dimension to DR diagnosis and prediction. Its ability to analyze complicated information, automate processes, and learn constantly renders it highly promising for enhancing efficacy, equity, and person-centered care (Hosseini *et al.*, 2019). Although there are remaining challenges, deep learning is leading the way in combating diabetes-induced blindness [6].

## **DEEP LEARNING FOR DR PREDICTION**

### **Convolutional Neural Networks (CNN)**

To predict a health condition called diabetic retinopathy, using special computer models like CNN is discussed. In conjunction with this, it would be explained how CNNs can assist in analyzing eye pictures and what is new about CNN designs to facilitate machine learning. This blindness always starts from the correct diagnosis by the physician, as well as promptness. For example, we have some advanced learning approaches known as CNNs that are aimed at examining images of the eyes, leading to another fight against the diseases of the organs of vision. Among other things, these are capable of analyzing retinal images just like human eyes do; therefore, they determine how items are organized into photographs. Inside them, students discuss various layers of unique filters that help learners understand shapes, textures, and motives behind different things.

## Global Perspective on Precision Medicine and Future Trends and Emerging Technologies

Shally<sup>1,\*</sup>, Nisha Wadhawan<sup>2</sup> and Ritika<sup>2</sup>

<sup>1</sup> Department of CSE-AIDS, Panipat Institute of Engineering and Technology, Samalkha, India

<sup>2</sup> School of Engineering & Technology, Apeejay Satya University, Gurugram, India

**Abstract:** Precision medicine is a revolutionary way of treating patients, with the hope that treatments can be more customized based on an individual's genome, environment, and lifestyle. Due to significant advances in genome sequencing, artificial intelligence, and big data analytics, the development of precision medicine is slowly progressing on a global scale. In this chapter, we explore precision medicine around the world and the evolution, adoption, and disparities of precision medicine across regions. Key drivers, including advancements in genomics, artificial intelligence, and molecular diagnostics, have propelled precision medicine to the forefront of modern healthcare. Emerging technologies such as CRISPR, wearable devices, and multi-omics platforms are already transforming precision medicine by finding the way to early diagnosis, personalized therapies, and real-time health monitoring. It also discusses how international collaboration, policy frameworks, and innovative financing models can help overcome barriers and ensure that these transformative solutions are available to all. Precision medicine's global adoption relies on advancing technologies, ethical considerations, and equitable access. The future perspective highlights the potential of an integrated global system to understand and leverage innovative technologies and precision medicine opportunities for a healthier and more equitable world in the future.

**Keywords:** Global health, Next-generation sequencing, Precision medicine, Patient, Treatment.

### INTRODUCTION

The average life expectancy has progressively increased over the last century [1]. Most people today would expect to live into their sixties and beyond, for the first time in history. One of the most important demographic trends in the world is population aging, and it is on track to become one of the biggest societal shifts of the 20<sup>th</sup> century, affecting every facet of society [2]. The growing burden of age-

---

\* **Corresponding author Shally:** Department of CSE-AIDS, Panipat Institute of Engineering and Technology, Samalkha, India; E-mails: shally.ngpl@gmail.com

related chronic diseases and accompanying healthcare expenses is among the main effects of a rapidly aging population. Cardiovascular disease, diabetes, neurological disorders, and the majority of malignancies are the most prevalent chronic diseases associated with an aging population. For the senior population worldwide, managing complicated chronic illnesses is becoming a major social and financial concern. It also poses a significant financial burden to national and international healthcare budgets [3].

Precision medicine is a new approach to treatment that considers individual differences in patients' genes, environment, and lifestyle. Precision medicine employs genetic, environmental, and lifestyle clues to deliver more precise diagnoses and tailored therapies, in contrast to conventional approaches that use one-size-fits-all procedures for treatment. This paradigm change has gained speed globally as medical care advances are driven by the fast growth of genomics, AI, and big data analytics. With a focus on patient-centricity everywhere, this is a global issue, yet each region faces different challenges in access, regulation, and patients requiring specialized healthcare solutions. Countries around the world are moving towards precision medicine at different rates due to different technological advancements, healthcare infrastructure, and economic reasons. The leaders in this regard are developed countries with strong research ecosystems and past investment experience, such as the United States, Germany, and the United Kingdom. However, the other extreme of the spectrum also faces challenges, such as limited financial resources and limited access to cutting-edge technologies. However, international collaborations such as the Human Genome Project and ongoing efforts in the Asian and African regions are bridging these gaps to make precision medicine available to diverse populations around the world [4].

At the core of this transformation are emerging technologies that enable breakthroughs never before possible in medicine. For example, analyzing large sets of data to identify new biomarkers and predict disease progression using AI and machine learning algorithms has been crucial. Also, CRISPR-based gene editing and Next-Generation Sequencing (NGS) technologies are changing the way diseases are diagnosed, prevented, and treated. These discoveries lead to a better understanding of complex diseases through precision medicine approaches such as immunotherapy and oncology. A combination of innovative technologies, interdisciplinary research, and international policy initiatives will shape the future of precision medicine. Wearable health devices, telemedicine, and sophisticated imaging technology should fill the space between real-time monitoring of health and early interventions. Finally, but most importantly, stakeholders will continue to address the societal challenges of precision medicine as ethical issues, data privacy, and equitable access will be priority issues in ensuring that precision medicine is inclusive and sustainable. If we understand the potential of emerging technologies and international collaboration, precision medicine has the potential

to transform healthcare delivery and improve clinical outcomes across entire populations at an unprecedented scale [5].

### **History of Precision Medicine**

The idea of customized medicine, although not new at the time, came into being in the 1990s as a result of automation and higher throughput in DNA sequencing technologies. Efforts like the Human Genome Project (HGP; 1990–2003) sprang from such advancements, elucidating and making accessible to researchers worldwide the sequences of over three billion base pairs of the human genome. Similarly, researchers were able to link gene variants to particular illnesses and disorders thanks to the International HapMap Project (2002–10), which found genetic variations that cause human disease. These developments provide insight into long-standing medical phenomena, such as the fact that some patients respond better to particular treatments than others and that some patients have abnormally severe side effects from others [6]. Advancements in the domains of pharmacogenomics and pharmacogenetics. The understanding of the molecular mechanisms underlying the impact of an individual's genetic makeup on disease and medicine has greatly increased as a result of the study of the genetic clarification of individual differences through drug responses and the examination of how various variations throughout the genome impact reactions to medicinal therapies. With the use of information from pharmacogenetics and pharmacogenomics, scientists were able to create more precise and objective tests for diagnosing diseases and forecasting how patients would react to treatment. Researchers discovered that the course or result of certain illnesses might be altered in some instances by utilizing genetic and other molecular data to guide diagnosis and therapy. Developments in medical information technology, which include electronic storage and processing of patient data, as well as in the practical application of customized medicine, especially *via* translational and clinical studies, further aided the rise of personalized medicine. Advances in those domains were crucial for integrating data from genomics and genetics research with clinical settings, including the usage of Electronic Health Records (EHRs), which include data on demographics, test results, medications, and histories for patients.

For instance, to better understand the reason certain blood transfusions were beneficial while others were fatal, Dr. Karl Landsteiner established the American Blood Type (ABO) method in 1901. The structure and function of RNA and DNA molecules were clarified by several other remarkable discoveries made by Phoebus Levene *et al.* [7]. These scientists' groundbreaking discoveries made it possible for researchers to link a variety of individual genetic and environmental variables to human health and illness for the first time in history. Researchers now

## SUBJECT INDEX

### A

Ability 22, 27, 41, 45, 48, 151, 152, 190, 191, 221, 222, 227, 228  
 Abnormalities 85, 98  
 Accountability 85, 100, 105, 107, 108, 165, 231, 252  
 Accuracy 3, 4, 5, 6, 7, 8, 15, 16, 17, 46, 146, 151, 205, 226, 227  
 ADRs (Adverse drug reactions) 121, 125, 129, 136, 137, 170, 207, 208  
 Advancements 7, 10, 157, 159, 170, 172, 232, 236, 238, 251, 253  
 Adverse drug reactions 125, 129, 136, 207, 208  
 Adverse effects 3, 36, 59, 122, 128, 173, 190, 192  
 Algorithms 36, 39, 45, 46, 47, 60, 63, 64, 99, 100, 101, 210, 212, 222  
 Application programming interface (API) 109  
 Applications 6, 7, 38, 39, 40, 90, 93, 107, 109, 111, 112, 158, 213, 214, 232  
 Architectures 4, 6, 109, 223, 225, 227  
 AUC (Area under curve) 6, 7, 46, 226

### B

Barriers 37, 164, 184, 214, 236  
  
 Benefits 23, 25, 26, 30, 70, 71, 169, 170, 203, 205, 222, 239, 240, 252, 253  
 Biases 88, 100, 155, 190, 203, 229, 231, 232  
 Bioinformatics 51, 53, 54, 57, 59, 68, 143, 147, 176, 184, 185  
 Biomarkers 52, 55, 56, 63, 70, 71, 137, 192, 193, 197, 198, 240, 245, 246, 254  
 Blockchain 95, 103, 104, 105, 107, 108, 109, 110, 111, 117, 118  
 Blockchain technology 103, 104, 105, 107, 108, 109, 110, 118

Body mass index (BMI) 32, 33, 184

### C

Cancer 34, 45, 64, 97, 159, 160, 183, 192, 194, 200, 201, 204, 205, 240, 245, 248  
 Cardiovascular diseases 34, 44, 55, 65, 68, 151, 172, 237, 241  
 Cells 56, 151, 179, 203, 243, 244  
 Challenges 25, 26, 37, 52, 60, 93, 122, 136, 172, 173, 226, 228, 230, 232, 251  
 Classification 6, 13, 17, 81, 82, 84, 85, 89, 90, 144, 149  
 Clinical data 66, 69, 183, 185, 196, 198, 202, 206, 211, 214, 249, 252  
 Clinical trials 23, 24, 25, 26, 59, 67, 135, 182, 183, 240, 247  
 Clinicians 2, 3, 8, 11, 23, 67, 166, 167, 176, 177, 214, 215, 216, 230, 232  
 CML (Chronic myeloid leukemia) 64, 94, 126, 134, 157, 168, 239  
 Collaboration 57, 58, 71, 72, 144, 147, 166, 167, 229, 230, 232  
 Convolutional neural network (CNNs) 3, 4, 6, 12, 14, 82, 84, 89, 90, 97, 199, 200, 220, 222, 223, 224, 225, 227  
 Costs 36, 37, 40, 42, 43, 67, 70, 137, 155, 157, 175, 176, 201, 202  
 CYP2C19 130, 132, 133, 134, 135  
 CYP2C9 65, 130, 132, 133, 135, 194  
 CYP2D6 127, 132, 133, 134, 135

### D

Data privacy 47, 48, 162, 163, 170, 215, 216, 231, 232, 237, 249, 251  
 Data protection 190, 201, 203, 212, 216  
 Data sources 23, 26, 144, 149, 190, 200, 202, 208, 213, 215, 216  
 Datasets 7, 9, 16, 17, 32, 46, 85, 86, 88, 89, 90, 197, 199, 201, 208

Decisions 69, 95, 99, 100, 149, 189, 193, 200, 239  
 Diagnosis 8, 9, 23, 24, 26, 47, 48, 51, 52, 90, 98, 99, 100, 221, 239  
 Diabetic retinopathy (DR) 44, 45, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 232, 233  
 Disease detection 8, 22, 47, 84, 151, 195, 197  
 Disease prevention 39, 158, 160, 239  
 Diseases 11, 34, 52, 53, 56, 60, 63, 71, 82, 90, 94, 125, 149, 160, 161, 172, 200, 211, 243, 245  
 Disorders 14, 45, 70, 92, 125, 126, 136, 199  
 Drug development 122, 135, 137, 191, 67, 129  
 Drug response 53, 64, 71, 121, 122, 125, 127, 128, 129, 131, 136  
 Drugs 35, 59, 64, 66, 94, 95, 121, 122, 125, 126, 127, 128, 129, 131, 132, 133, 134, 135, 136, 137

**E**

Early detection 3, 8, 11, 200, 203, 211, 212, 221, 225, 227, 233  
 Early interventions 39, 41, 69, 148, 149, 183, 184, 224, 226, 237  
 Efficacy 5, 6, 23, 25, 42, 43, 58, 127, 129, 135, 192, 205, 206, 250  
 Electronic health record (EHR) 25, 26, 39, 207, 253  
 Enzymes 35, 127, 130, 132, 239  
 Ethical considerations 72, 81, 86, 153, 155, 166, 231, 232, 236, 253  
 Ethical issues 57, 58, 121, 136, 162, 185, 220, 231, 232, 237  
 Evaluation 5, 9, 10, 11, 16, 23, 46, 104, 128, 189, 191  
 Evolution 53, 157, 168, 236, 243, 254

**F**

Factors 82, 129, 250, 121, 122, 128, 136, 194  
 FDA (Food and drug administration) 124, 125, 126, 131, 250, 254  
 Federated learning (FL) 21, 48, 82, 85, 99, 100, 215, 216

Findings 25, 28, 68, 71, 149, 193, 196, 205, 206, 211, 212, 236, 239  
 Frameworks 7, 13, 23, 46, 62, 88, 106, 108, 111, 165, 166

**G**

General data protection regulation (GDPR) 38, 57, 99, 152, 162, 163, 174, 196, 215  
 Genes 60, 61, 92, 94, 121, 122, 125, 127, 129, 130, 133, 192, 194, 243, 244  
 Genetic data 39, 57, 59, 66, 67, 69, 150, 151, 155, 156, 176, 183, 213, 214, 251  
 Genetic information 53, 54, 55, 57, 122, 125, 128, 162, 163, 174, 248, 251, 252  
 Genetic mutations 53, 56, 60, 65, 157, 253  
 Genetic profiles 36, 54, 55, 59, 64, 65, 66, 67, 72, 93, 169  
 Genetic research 58, 92, 199, 206, 238, 242, 243, 252, 253  
 Genetic variations 52, 53, 60, 62, 64, 68, 69, 71, 127, 129, 136, 137  
 Genetics 53, 55, 57, 59, 64, 66, 67, 92, 93, 128, 129, 147, 199, 201, 243  
 Genomic data 51, 52, 181, 182, 183, 195, 197, 198, 205, 207, 208, 210, 253  
 Genomics 51, 52, 53, 54, 55, 56, 57, 63, 67, 68, 158, 176, 183, 203, 243

**H**

Health outcomes 24, 30, 40, 55, 143, 149  
 Healthcare providers 26, 30, 41, 48, 106, 107, 148, 152, 157, 181, 183, 184  
 Healthcare systems 21, 23, 24, 36, 58, 60, 104, 105, 144, 145, 162, 163, 194, 240, 241  
 Heart disease 39, 46, 69, 70, 92, 93, 95, 101, 145, 149, 157  
 HIPAA (Health insurance portability and accountability act) 26, 99, 147, 152, 162, 174, 196  
 Human genome project (HGP) 53, 64, 157, 168, 192, 237, 238, 243

## **Subject Index**

### **I**

Identification 53, 54, 62, 125, 127, 128, 129, 131, 135, 137, 145  
Illnesses 7, 8, 9, 10, 11, 43, 44, 45, 145, 178, 179, 194, 238, 239, 241  
Images 4, 5, 6, 12, 13, 14, 83, 84, 86, 87, 88, 89, 98, 99, 100  
Imaging 67, 68, 90, 91, 92, 96, 97, 98, 101, 200, 203, 211, 215  
Imaging data 81, 82, 90, 91, 96, 97, 98, 99, 100, 195, 196, 197, 198  
Implementation 57, 58, 103, 106, 107, 118, 122, 136, 137, 163, 164, 212, 214  
Infrastructure 37, 51, 93, 174, 177, 215, 216, 240, 249, 251, 254  
Integration 96, 98, 125, 172, 177, 184, 195, 214, 216, 249, 255  
Interventions 25, 63, 64, 65, 98, 101, 145, 221, 222, 232, 240  
IoT (Internet of things) 48, 196, 203, 204, 212, 215, 216

### **K**

K-means clustering 7, 198, 208  
Knowledge 32, 92, 100, 125, 143, 144, 203, 209, 222, 239

### **L**

Large datasets 81, 84, 85, 190, 192, 198, 199, 200, 202, 206, 211  
Layers 2, 4, 14, 165, 222, 223, 227  
Lifestyle 34, 39, 52, 55, 60, 62, 65, 158, 192, 236, 237

### **M**

Machine learning algorithms 7, 8, 10, 11, 36, 37, 39, 42, 45, 81, 82, 201, 202, 210, 211  
Machine learning models 10, 11, 86, 87, 89, 99, 145, 146, 190, 200, 203  
Machine learning techniques 83, 193, 206

## **Precision Medicine: Improving Healthcare 259**

Management 10, 38, 65, 68, 71, 170, 189  
Medical data 21, 33, 95, 105, 106, 108, 111, 161, 183  
Medical history 37, 39, 144, 148, 149, 150, 222, 223, 224, 225, 228, 230  
Medical images 34, 42, 43, 81, 84, 88, 97, 98, 149, 213  
Medications 23, 24, 25, 35, 36, 91, 92, 128, 131, 192, 194, 238, 239, 240, 245  
Medicine 21, 35, 36, 56, 57, 92, 95, 96, 143, 194, 200, 237, 238, 248, 249  
Methods 9, 14, 17, 29, 30, 34, 198, 199, 208, 209, 210, 225, 229  
Models 4, 11, 15, 16, 17, 41, 46, 86, 98, 99, 100, 148, 200, 205, 224, 225, 226, 228, 229, 230  
Mutations 55, 56, 59, 62, 64, 67, 92, 239, 243, 244, 245

### **N**

Next-generation sequencing (NGS) 53, 54, 56, 60, 61, 69, 92, 94, 157, 158, 204, 236, 237, 240, 244  
Number 12, 15, 24, 27, 30, 40, 44, 48, 56, 216, 250, 252, 253

### **O**

Outcomes 23, 24, 29, 33, 38, 41, 52, 54, 55, 68, 70, 72, 179

### **P**

Patient care 27, 30, 36, 37, 40, 90, 92, 97, 144, 150, 245, 248, 251  
Patient data 39, 41, 103, 104, 106, 147, 149, 150, 163, 200, 201, 202, 205  
Patient outcomes 1, 22, 36, 38, 39, 41, 55, 56, 60, 147, 148, 152, 153, 190, 192  
Patients 7, 34, 37, 40, 41, 55, 71, 95, 104, 111, 125, 128, 162, 163, 164, 178, 182, 194, 240, 250  
Performance 15, 16, 17, 27, 146, 166, 199

Personalized medicine 51, 52, 53, 54, 55, 56, 57, 58, 59, 63, 65, 66, 67, 69, 71, 72, 157, 158, 159, 239

Personalized treatments 54, 60, 63, 159, 160, 168, 172, 177, 183, 195, 197

Pharmacogenomics 64, 65, 92, 93, 121, 122, 125, 127, 128, 129, 135, 136, 137, 158, 238

Platforms 25, 57, 94, 103, 109, 150, 181, 184, 195, 248, 250

Precision 4, 5, 13, 15, 16, 17, 60, 70, 71, 164, 165, 205, 206

Precision medicine 72, 81, 180, 177, 172, 173, 181, 183, 193, 198, 208, 253, 236, 169

Predictions 3, 5, 8, 9, 34, 41, 42, 222, 223, 224, 226, 227, 228, 229, 230

Predictive analytics 21, 22, 28, 39, 41, 43, 146, 147, 150, 152, 195, 196, 197, 200, 201

Predictive models 22, 48, 69, 144, 145, 147, 149, 203

Privacy 57, 72, 85, 86, 99, 103, 105, 106, 109, 174, 177, 251, 254

Problems 36, 37, 95, 189, 190, 196, 199, 200, 201, 202, 203, 205, 212, 213, 216

Proteomics 52, 60, 70, 71, 82, 158, 168, 181, 192, 202, 208

## R

Random forest (RF) 46, 85, 89, 184, 189, 197, 198, 205, 206, 207, 208, 210, 216

Real-time monitoring 82, 203, 204, 212, 213, 237

Regulations 58, 100, 122, 130, 131, 165, 172, 231, 237

Relationships 32, 33, 116, 127, 137, 199, 243

Research 4, 127, 167, 161, 169, 183, 251

Resources 22, 57, 82, 112, 144, 150, 152, 161, 177, 182, 205

Response 1, 33, 42, 55, 63, 64, 122, 125, 128, 134, 135

Risk 35, 36, 44, 46, 88, 90, 91, 92, 130, 131, 144, 212, 213, 223, 224

Risk factors 25, 64, 69, 228, 33, 144

Role 55, 87, 93, 117, 122, 125, 129, 132, 135, 231, 239

## S

Safety 23, 35, 64, 65, 68, 129, 135, 165, 196, 250

Science 157, 164, 250

Scientists 34, 72, 128, 156, 157, 168, 169, 230, 238, 243, 244

Security 57, 105, 109, 111, 152, 153, 162, 163, 165, 231, 249, 251, 254

Sequencing 53, 54, 70, 181, 242, 244

Side effects 35, 36, 55, 65, 66, 67, 92, 93, 94, 151, 152, 201, 204, 238, 240

Solutions 1, 10, 162, 172, 173, 175, 176, 177, 181, 226, 232

Stakeholders 32, 106, 109, 166, 232, 237, 254

Strategies 9, 34, 106, 118, 144, 183, 185, 191, 242, 245, 246

Support vector machines (SVMs) 4, 5, 85, 89, 149, 184, 189, 193, 197, 205, 206

Symptoms 2, 3, 11, 23, 24, 34, 37, 55, 60, 200, 204

## T

Targeted therapies 40, 53, 67, 92, 94, 157, 159, 170, 175, 239, 245

Techniques 9, 14, 17, 29, 30, 34, 198, 199, 208, 209, 210, 225, 229

Technologies 21, 22, 26, 30, 36, 44, 48, 51, 54, 57, 70, 90, 101, 136, 137, 151, 157, 158, 159, 162, 163, 164, 166, 170, 174, 181, 183, 192, 196, 215, 216, 231, 236, 237, 241, 242, 243, 244, 247, 248, 249, 250, 252

Therapies 22, 23, 55, 58, 59, 60, 67, 70, 71, 143, 144, 145, 149, 240, 250

Tools 51, 52, 86, 88, 92, 98, 99, 101, 149, 150, 205, 211, 215

Training 6, 9, 13, 15, 17, 84, 87, 88, 93, 222, 225, 226, 231

Transparency 47, 62, 100, 104, 165, 230, 231

Treatment plans 39, 51, 91, 94, 95, 147, 149, 152, 196, 197, 201, 203

**Subject Index**

Trends 15, 16, 22, 24, 29, 32, 34, 82, 85, 143,  
144, 147, 149, 168, 184, 192, 195,  
196, 200, 202, 203, 236  
Trials 23, 24, 26, 35, 36, 58, 63, 67, 109, 122,  
125, 135, 136, 179, 202, 247, 250,  
252  
Tumors 34, 40, 44, 64, 70, 84, 88, 90, 92, 94,  
98

**U**

Utilization 21, 46, 48, 135, 137

**V**

Validation 5, 24, 105, 106, 112, 118, 121, 148,  
183, 225, 247, 254  
Variables 7, 11, 23, 26, 31, 32, 33, 45, 144,  
146, 148, 150, 180, 224, 238, 249,  
250  
Variations 8, 53, 61, 62, 86, 87, 88, 91, 93,  
122, 127, 128, 129, 130, 168, 179,  
192, 194, 199, 221, 238, 253  
VGG16 13, 14, 15, 16, 17, 227

**W**

Warfarin 65, 127, 128, 129, 130, 133, 239  
Work 98, 99, 100, 106, 107, 115, 118, 145,  
193, 194, 195, 196, 197, 199, 200,  
201, 221, 242



## Prasad Lokulwar

---

Dr. Prasad Lokulwar is a Professor and In-charge of the Centre of Excellence (Digital Technology) in the Department of Computer Science and Engineering at G. H. Rasoni College of Engineering (Autonomous), Nagpur, India. He holds a Ph.D. from Sant Gadge Baba Amravati University and is currently pursuing a postdoctoral fellowship at Lincoln University College, Malaysia. A Senior Member of IEEE and Life Member of ISTE, he has over fifteen years of teaching and research experience. He has published 65 research papers, authored six books including a Scopus-indexed volume, and holds 18 patents and eight copyrights. He has supervised Ph.D. scholars and numerous student projects and received prestigious honors including the ISTE Maharashtra State National Award for Outstanding Research in Engineering and Technology (2024).



## Basant Kumar Verma

---

Prof. (Dr.) Basant Kumar Verma is a Professor and Head of the Department of Computer Science Engineering (Artificial Intelligence & Data Science) at Panipat Institute of Engineering and Technology (PIET), Haryana, India, and Vice President of the University of Digital and AI Management (UniDAIM), USA. He has over 20 years of academic, research, and industry experience in Artificial Intelligence, Data Science, Big Data Analytics, and Machine Learning. He earned his B.E. and M.E. from BITS Pilani and a Ph.D. in Computer Science and Engineering from Shridhar University, Pilani. Dr. Verma has published numerous research papers in reputed journals and IEEE conferences, authored several books, and holds multiple national and international patents in AI, IoT, and data-driven technologies. He actively contributes to international conferences, keynote lectures, and academic leadership in emerging technologies.



## Mitu Sehgal

---

Dr. Mitu Sehgal is working as an Assistant Professor in the Department of Computer Science – Artificial Intelligence and Data Science at Panipat Institute of Engineering & Technology. She has 13 years of teaching experience. She has presented and published several papers in conferences and journals and has served as a coordinator for many conferences at the institute level. She has attended multiple Faculty Development Programs (FDPs) and workshops on national and international platforms. She has also published several patents at national and international levels. Her areas of interest include Machine Learning and IoT.



## Kailash Kumar

---

Dr. Kailash Kumar is an Assistant Professor and Program Coordinator (BSIT) at the College of Computing and Informatics, Saudi Electronic University, Riyadh, KSA. He has over 17 years of teaching and academic experience and previously served as Dean (Academics) at the Modern Institute of Technology & Research Centre, India. He has published numerous research papers, authored a book on Theory of Computation, contributed chapters to several books, and received IBM's Explorer and Mastery Awards – IoT Cloud Developer. He is a reviewer for reputed international journals and actively engages in research in Data Science, Machine Learning, AI, Blockchain, E-commerce, and Compiler Construction. He is a member of multiple national and international professional societies, including IEEE, CSI, ISTE, IAENG, and AMIE.



## Mohan Lal Kolhe

---

Prof. Dr. Mohan Lal Kolhe is a Full Professor of Smart and Sustainable Electrical Energy Systems with Renewables and Hydrogen at the University of Agder, Norway. He has over 30 years of international academic leadership and has held positions at top institutions, including University College London, University of Dundee, the University of Jyväskylä (Finland), and the Hydrogen Research Institute (Canada). He has contributed to renewable energy policy as a member of South Australia's first Renewable Energy Board and secured funding from agencies such as the European Union, Norwegian Research Council, EPSRC, and BBSRC. His research focuses on renewable energy systems, hydrogen technologies, smart grids, and sustainable energy integration. He has an h-index of 37, is ranked among the top 2% of scientists worldwide, and actively participates in international research assessment, conferences, and global energy initiatives.